alendronate has been researched along with risedronic acid in 427 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (2.34) | 18.2507 |
| 2000's | 253 (59.25) | 29.6817 |
| 2010's | 131 (30.68) | 24.3611 |
| 2020's | 33 (7.73) | 2.80 |
| Authors | Studies |
|---|---|
| Bailey, BN; Docampo, R; Rodriguez, JB; Szajnman, SH | 1 |
| Bailey, BN; Caldera, A; Croft, SL; Docampo, R; Grimley, JS; Heath, HT; Kendrick, H; Lewis, JC; Lira, R; Martin, MB; Moreno, SN; Oldfield, E; Urbina, JA; Yardley, V | 1 |
| Cieslak, JA; Coates, RM; Fukura, S; Koohang, A; Lea, CR; Lee, HJ; Loftus, TC; Martin, MB; Matsumura, Y; Oldfield, E; Sagami, H; Sanders, JM; Sengupta, S; Szabo, CM | 1 |
| Martin, MB; Oldfield, E; Szabo, CM | 1 |
| Burzynska, A; Gómez, AO; González-Pacanowska, D; Kafarski, P; Mao, J; Meints, GA; Oldfield, E; Sanders, JM; Van Brussel, EM | 1 |
| Bruchhaus, I; Chan, JM; Croft, SL; Flessner, RM; Ghosh, S; Kemp, RG; Kendrick, H; Kobayashi, S; Lea, CR; Lewis, JC; Loftus, TC; Meints, GA; Nozaki, T; Oldfield, E; Tovian, ZS | 1 |
| Burzynska, A; Chan, JM; Colantino, A; Ghosh, S; Kafarski, P; Meints, G; Morita, CT; Oldfield, E; Raker, AM; Sanders, JM; Song, Y; Wang, H | 1 |
| Chan, JM; Flessner, R; Gómez, AO; González-Pacanowska, D; Jennings, S; Kosztowski, T; Kotsikorou, E; Meints, GA; Morita, CT; Odeh, S; Oldfield, E; Papapoulos, SE; Raker, AM; Sanders, JM; Schwerdtfeger, C; Song, Y; van Beek, ER; Wang, H; Zhang, Y | 1 |
| Araujo, FG; Chan, JM; Ling, Y; Moreno, SN; Odeh, S; Oldfield, E; Sahota, G | 1 |
| Barnett, BL; Dunford, JE; Ebetino, FH; Kavanagh, KL; Kwaasi, AA; Oppermann, U; Rogers, MJ; Russell, RG | 1 |
| Blackburn, GM; Brown, RJ; Carran, J; Hounslow, AM; Rejman, D; Watts, DJ | 1 |
| Axelson, J; Cao, R; Chang, SC; Chang, TH; Guo, RT; Hudock, MP; K-M Chen, C; Ko, TP; Kumar, A; Liang, PH; No, JH; Oldfield, E; Song, Y; Wang, AH; Zhang, Y | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Berlicki, Ł; Kafarski, P; Mucha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Agamennone, M; Angelelli, M; Cellamare, S; Dimiccoli, V; Laghezza, A; Marobbio, CMT; Perna, F; Profilo, E; Purgatorio, R; Savino, S; Scala, R; Scilimati, A; Tolomeo, A; Tortorella, P; Toscano, A; Tricarico, D; Vitale, P | 1 |
| Abdelmagid, WM; Mahmoodi, N; Tanner, ME | 1 |
| Artyushin, OI; Brel, VK; Chuprov-Netochin, RN; Leonov, SV; Semenov, VV; Semenova, MN | 1 |
| Altman, RA; Borel, T; Davis, I; de Azambuja, F; Johnson, D; Liu, A; Sorrentino, JP; Udokwu, C; Yang, Y | 1 |
| Almeida Paz, FA; Barbosa, JS; Braga, SS | 1 |
| Bauss, F; Bosies, E; Fleisch, H; Janner, M; Mühlbauer, RC; Schenk, R; Strein, K | 1 |
| Licata, AA | 1 |
| Berman, SK; Blank, MA; Ems, BL; Gibson, GW; Myers, WR; Phipps, RJ; Smith, PN | 1 |
| Coxon, FP; Graham, R; Hughes, DE; Luckman, SP; Rogers, MJ; Russell, G | 1 |
| Kindt, MV; Majka, JA; Peter, CP | 1 |
| Handt, LK; Peter, CP; Smith, SM | 1 |
| Ebetino, FH; Löwik, CW; Papapoulos, SE; van Beek, ER | 1 |
| Dunlop, MB; Lane, NE | 1 |
| Halasy-Nagy, JM; Masarachia, PJ; Reszka, AA; Rodan, GA | 1 |
| Hamdy, RC | 1 |
| Berenson, J; Hortobagyi, G; Lipton, A; Major, PP | 1 |
| Burr, DB; Forwood, MR; Hirano, T; Johnston, CC; Mashiba, T; Turner, CH | 1 |
| Brown, RJ; Grove, JE; Watts, DJ | 1 |
| Prestwood, KM; Raisz, LG | 2 |
| Blank, MA; Dierckman, TA; Gibson, GW; Myers, WR; Phipps, RJ; Smith, PN | 1 |
| Blank, MA; Hunt, RH; Lanza, FL; Provenza, JM; Thomson, AB | 1 |
| Kronenberg, HM; Leder, BZ | 1 |
| Dijkmans, BA; Lems, WF | 1 |
| Blank, MA; Gibson, GW; Lichtenberger, LM; Romero, JJ | 1 |
| Baran, DT | 1 |
| Mackey, MS; Mosekilde, L; Phipps, RJ; Thomsen, JS | 1 |
| Graham, DY; Lanza, F; Malaty, HM; Musliner, T; Quan, H; Reyes, R; Sahba, B; Schwartz, H | 1 |
| Papapoulos, SE | 1 |
| Fisher, JE; Reszka, AA; Rodan, GA | 1 |
| Compston, JE | 1 |
| Watts, NB | 1 |
| Irani, M | 1 |
| Brown, JP; Drake, WM; Kendler, DL | 1 |
| McCormack, J | 1 |
| Blank, MA; Thomson, AB | 1 |
| Cefalu, CA | 1 |
| Netelenbos, JC | 1 |
| Bukowski, JF; Das, H; Kamath, A; Wang, L | 1 |
| McClung, B; McClung, M | 1 |
| Boyce, EG; Umland, EM | 1 |
| Leonard, M; Licata, AA; Peters, ML | 1 |
| Halasy-Nagy, JM; Reszka, AA; Rodan, GA | 1 |
| Burr, DB; Li, J; Mashiba, T | 1 |
| Trémollières, F | 1 |
| Kruse, HP | 1 |
| Adachi, JD; Adami, S; Gomez-Panzani, E; Kendler, DL; Li, Z; Licata, AA; Miller, PD; Olszynski, WP; Silverman, SL | 1 |
| Duthie, EH; Kamel, HK | 1 |
| Hanley, DA; Hodsman, AB; Josse, R | 1 |
| Baker, DE | 1 |
| Välimäki, MJ | 1 |
| Graham, DY | 1 |
| Adachi, JD; Kherani, RB; Papaioannou, A | 1 |
| Blank, MA; Hunt, RH; Lanza, FL; Li, Z; Marshall, JK; Provenza, JM; Royer, MG; Thomson, AB | 1 |
| Diez-Perez, A | 1 |
| Khosla, S; Tremaine, WJ | 1 |
| Deal, C; Srivastava, M | 1 |
| Phipps, RJ; Scutt, A; Still, K | 1 |
| Begerow, B; Hinz, C; Minne, HW; Pfeifer, M; Pollähne, W | 1 |
| Deal, CL | 1 |
| Bartl, R | 2 |
| Sohen, S | 1 |
| Appleman, S; Keelan, M; Thomson, AB; Wallace, JL | 1 |
| Ringe, JD | 2 |
| Derman, R | 1 |
| Reid, IR | 2 |
| Traut, V | 1 |
| Adami, S; Andia, JC; Benhamou, L; Felsenberg, D; Hosking, D; Petruschke, RA; Reginster, JY; Rybak-Feglin, A; Santora, AC; Välimäki, M; Yacik, C; Zaru, L | 1 |
| Ettinger, MP | 1 |
| Burr, DB; Day, JS; Ding, M; Hirano, T; Hvid, I; Mashiba, T; Sumner, DR; Weinans, H | 1 |
| Taha, EA; Youssef, NF | 1 |
| Boyde, A; Burr, DB; Grynpas, M; Hirano, T; Johnston, CC; Li, J; Mashiba, T; Miller, L | 1 |
| Cohen, SB | 1 |
| Kessenich, C | 1 |
| Hatzigeorgiou, C; Jackson, JL; Tofferi, JK; Wei, GS | 1 |
| Matsumoto, T | 2 |
| Ohta, H | 1 |
| Im, GI; Kenney, J; Qureshi, SA; Rubash, HE; Shanbhag, AS | 1 |
| Aihara, E; Kanatsu, K; Kato, S; Okayama, M; Takeuchi, K | 1 |
| Curković, B | 1 |
| Bednarz, P; Burr, DB; Day, JS; Ding, M; Hirano, T; Hvid, I; Johnston, CC; Mashiba, T; Sumner, DR; van der Linden, JC; Weinans, H | 1 |
| Hershman, D; Narayanan, R | 1 |
| Saag, KG | 1 |
| Ott, S | 1 |
| Marx, J | 1 |
| Zizic, TM | 1 |
| Emkey, R | 1 |
| Keller, MI | 1 |
| Adachi, JD | 1 |
| Brecht, JG; Huppertz, E; Kruse, HP; Möhrke, W; Oestreich, A | 1 |
| Sarioglu, M; Taneli, F; Tikiz, C; Tuzun, C; Unlu, Z; Uyanik, BS | 1 |
| Kendler, DL; Li, WW | 1 |
| Bonnick, SL; Broy, S; Chen, E; de Papp, AE; Hochberg, MC; Kagan, R; McClung, M; Miller, P; Petruschke, RA; Rosen, CJ; Thompson, DE | 1 |
| Abe, E; Fallon, JT; Fisher, EA; Shimshi, M; Zaidi, M | 1 |
| Bonnick, SL; Chen, E; de Papp, AE; Kagan, R; Sebba, AI; Skalky, CS; Thompson, DE | 1 |
| Chang, JT; Wysowski, DK | 1 |
| Hosking, DJ; Pande, I | 2 |
| Chapurlat, RD | 1 |
| Awayda, MS; Orlando, RC; Shao, W | 1 |
| Abrahamsen, B; Brixen, KT; Kassem, MS; Mosekilde, L | 1 |
| Høiseth, A | 1 |
| Brewer, N; Davis, S; De Nigris, E; Jones, ML; Oakley, J; Stevenson, M | 1 |
| Delmas, PD | 1 |
| Barton, IP; Boonen, S; Laan, RF; Watts, NB | 1 |
| Armitage, GC; Hsieh, S; Jeffcoat, M; Lane, N; Loomer, P; Majumdar, S; Munoz, T; Wang, HY | 1 |
| McClung, M | 1 |
| Maricic, M | 2 |
| Rackoff, PJ; Sebba, A | 1 |
| Altman, R; Amonkar, MM; Cramer, JA; Hebborn, A | 1 |
| Burr, DB; Hui, S; Johnston, CC; Mashiba, T; Mori, S; Turner, CH | 1 |
| García, LL; Muñoz, VL; Roger, DR; Valle, MB | 1 |
| Amzel, LM; Docampo, R; Gabelli, SB; McLellan, JS; Montalvetti, A; Oldfield, E | 1 |
| Chesnut, CH; Gass, ML; Hamdy, RC; Holick, MF; Leib, ES; Lewiecki, ME; Maricic, M; Watts, NB | 1 |
| Christoffersen, H; Holmegaard, SN | 1 |
| Orcel, P | 1 |
| Liel, Y | 1 |
| Dobnig, H; Fahrleitner-Pammer, A; Hofbauer, LC; Obermayer-Pietsch, B; Viereck, V | 1 |
| Delaney, MF | 1 |
| Takada, J | 1 |
| Allison, J; Curtis, JR; Freeman, A; Kovac, SH; Saag, KG; Westfall, AO | 1 |
| Delmas, PD; Emkey, R; Epstein, S; Hiltbrunner, V; Schimmer, RC; Wilson, KM | 1 |
| Hillman, JJ; Lee, E; Wutoh, AK; Xue, Z; Zuckerman, IH | 1 |
| Khapra, AP; Rose, S | 1 |
| Dawson-Hughes, B; Gass, M | 1 |
| Burr, DB; Miller, LM; Ruppel, ME | 1 |
| Naunton, M | 1 |
| Franke, HR; Verdijk, R; Vermes, I; Wolbers, F | 1 |
| Bonnick, S; Burnett, SM; Chen, E; de Papp, AE; Hochberg, M; Kagan, R; Kiel, DP; McClung, M; Saag, KG; Sebba, A; Thompson, DE | 1 |
| Erkens, JA; Goettsch, WG; Herings, RM; Penning-van Beest, FJ | 1 |
| Bivi, N; Deganuto, M; Moro, L; Pines, A; Quadrifoglio, F; Romanello, M; Tell, G | 1 |
| Iwamoto, J; Sato, Y; Takeda, T | 2 |
| Allison, JJ; Curtis, JR; Freeman, A; Saag, KG; Westfall, AO | 1 |
| Hochberg, MC; Rizzoli, R | 1 |
| Allen, MR; Burr, DB; Iwata, K; Phipps, R | 1 |
| Boccuzzi, SJ; Downey, TW; Foltz, SH; Kahler, KH; Omar, MA | 1 |
| Burr, DB; Follet, H; Iwata, K; Li, J; Phipps, RJ | 1 |
| Adachi, J; Blackhouse, G; Goeree, R | 1 |
| Chapurlat, RD; Delmas, PD | 1 |
| Langdahl, B; Mosekilde, L; Vestergaard, P | 1 |
| Adami, S; Agnusdei, D; Gentilella, R; Iori, N; Isaia, G; Luisetto, G; Minisola, S; Nuti, R; Sinigaglia, L | 1 |
| Carter, JD; Cruse, LM; Valeriano, J; Vasey, FB | 1 |
| Allen, MR; Burr, DB; Follet, H; Khurana, M; Sato, M | 1 |
| Basir, YJ; Briscoe, C; Kafonek, C; Lapko, VN; Lee, JW; Olsen, R; Zhu, LS | 1 |
| Delmas, PD; Lange, JL; Lindsay, R; Silverman, SL; Watts, NB | 2 |
| Adachi, JD; Beattie, K; Bobba, RS; Kumbhare, D; Parkinson, B | 1 |
| Brandi, ML; Gaines, KA; Hosking, D; Kendler, D; Marques-Neto, JF; Melton, ME; Reid, DM; Verbruggen, N; Wark, JD; Weryha, G | 1 |
| Briot, K; Roux, C; Thomas, T; Trémollières, F | 1 |
| Burr, DB; Condon, K; Follet, H; Hui, S; Li, J; Phipps, RJ | 1 |
| Gold, DT; Iolascon, G; Jodar, E; Keen, R; Kruse, HP; Mann, B; Varbanov, A | 1 |
| Botsis, D; Christodoulakos, G; Lambrinoudaki, I | 1 |
| Chen, SH; Chen, YJ; Hall, BJ; Khan, MA; Kung, AW; Mirasol, R; Pasion, EG; Shah, GA; Sivananthan, SK; Tam, F; Tay, BK; Thiebaud, D | 1 |
| Iba, K; Imoto, K; Takada, J; Yamashita, T | 1 |
| Arnold, M; Avorn, J; Brookhart, MA; Finkelstein, JS; Katz, JN; Mogun, H; Patrick, AR; Polinski, JM; Solmon, DH | 1 |
| Sato, S | 1 |
| Epstein, S | 1 |
| Beirne, JC; Khosa, AD; Nayyar, MS | 1 |
| Akçay, A; Bavbek, N; Inegöl, I; Kanbay, M; Turgut, FH; Uz, E; Yanik, B; Yanik, T | 1 |
| Díaz-Curiel, M; Moro Alvarez, MJ | 1 |
| Malden, NJ; Pai, AY | 1 |
| Camm, J; Karam, R; McClung, M | 1 |
| Akasaka, E; Kamatari, M; Koto, S; Ozawa, N; Sakota, K; Suzuki, Y; Urao, C; Yanagimoto, K | 1 |
| Allen, MR; Burr, DB | 1 |
| Civitelli, R; Emkey, R; Strampel, W | 1 |
| Fugazzotto, PA; Jaffin, R; Kumar, A; Lightfoot, WS | 1 |
| Hawker, G; Kopp, A; Mamdani, M | 1 |
| Rizzoli, R | 1 |
| Christodoulakos, GE; Marín, F; Mellström, D; Nickelsen, T; Pavo, I; Petto, H; Ringe, JD | 1 |
| Nakayama, H | 1 |
| Reginster, JY | 1 |
| Adachi, JD; Grima, DT; Papaioannou, A; Pasquale, MK; Thompson, MF | 1 |
| Cillo, JE; Marx, RE; Ulloa, JJ | 1 |
| Alva, D; Cesareo, R; Contini, S; De Rosa, B; Iozzino, M; Lauria, A; Mallardo, L; Napolitano, C; Orsini, A; Reda, G | 1 |
| Allen, MR; Burr, DB; Delmas, PD; Gineyts, E; Leeming, DJ | 1 |
| Oshima, H; Tanaka, I | 1 |
| Nakamura, T; Narusawa, K | 1 |
| Kishimoto, H | 1 |
| Mukherjee, S; Oldfield, E; Song, Y | 1 |
| Katayama, K; Matsuno, T | 1 |
| Adami, S; Agnusdei, D; Gentilella, R; Isaia, G; Luisetto, G; Minisola, S; Nuti, R; Silvestri, S; Sinigaglia, L | 1 |
| Brandi, ML; Hosking, D; Hustad, CM; Kendler, D; Mahlis, EM; Marques-Neto, JF; Melton, ME; Reid, DM; Verbruggen, N; Wark, JD; Weryha, G | 1 |
| Coxon, FP; Ebetino, FH; Roelofs, AJ; Rogers, MJ; Thompson, K | 1 |
| Crail, DJ; Dansereau, RJ; Perkins, AC | 1 |
| Erkens, JA; Herings, RM; Olson, M; Penning-van Beest, FJ | 1 |
| Khan, A | 1 |
| Brookhart, MA; Cadarette, SM; Katz, JN; Solomon, DH; Stedman, MR; Stürmer, T | 1 |
| Blouin, J; Dragomir, A; Fernandes, JC; Moride, Y; Perreault, S; Ste-Marie, LG | 1 |
| Adams, JS; Geller, JL; Hu, B; Mirocha, J; Reed, S | 1 |
| Burr, DB; Fuchs, RK; Phipps, RJ | 1 |
| Adami, S; Bianchi, G; Di Munno, O; Fiore, CE; Giannini, S; Minisola, S; Rossini, M; Sinigaglia, L | 1 |
| Atherton, CT; Blackshaw, PE; Dansereau, RJ; Hay, PD; Lawes, SC; Perkins, AC; Schnell, DJ; Spiller, RC; Wagner, LK | 1 |
| Allen, MR; Burr, DB; Fyhrie, DP; Jeremić, B; Lavernia, EJ; Wang, X | 1 |
| Martens, MG; Shaw, H | 1 |
| Iizuka, T; Matsukawa, M | 1 |
| Adachi, J; Bilezikian, JP; Boonen, S; Delmas, PD; Greenspan, SL; Lang, TF; Lindsay, R; Luckey, M; Meeves, S; Miller, PD; Saag, K; Seeman, E; Watts, NB | 1 |
| Hochberg, MC | 1 |
| Burge, RT; Lindsay, R; Marshall, DA; Tosteson, AN | 1 |
| Beck, TJ; Bonnick, SL; Cosman, F; de Papp, AE; Hochberg, MC; Wang, H | 1 |
| Silverman, SL | 1 |
| Lakhotia, SM | 1 |
| Olson, M; Rietbrock, S; van Staa, TP | 1 |
| Hatakeyama, N; Iba, K; Ozasa, Y; Takada, J; Wada, T; Yamashita, T | 1 |
| Allen, MR; Burr, DB; Phipps, R; Tang, SY; Vashishth, D | 1 |
| Cheng, H; Curtis, JR; Delzell, E; Saag, KG; Westfall, AO | 1 |
| Verhaar, HJ | 1 |
| Barbeau, M; Kindundu, CM; LeLorier, J; Sheehy, O | 1 |
| Blouin, J; Dragomir, A; Fernandes, JC; Fredette, M; Perreault, S; Ste-Marie, LG | 1 |
| Okazaki, R | 1 |
| Foo, AC; Glendenning, P; Inderjeeth, CA; Lai, MM | 1 |
| Stepan, JJ; Zikan, V | 1 |
| Bilezikian, JP | 1 |
| Brookler, K | 1 |
| Fujii, Y; Fujita, T; Miyauchi, A; Ohue, M; Takagi, Y | 1 |
| Geusens, P | 1 |
| Douglas, I; Grosso, A; Hingorani, A; MacAllister, R; Smeeth, L | 1 |
| Brookhart, MA; Cadarette, SM; Katz, JN; Levin, R; Solomon, DH; Stedman, MR; Stürmer, T | 1 |
| Allen, MR; Burr, DB; Erickson, AM; Hazelwood, SJ; Martin, RB; Wang, X | 2 |
| Levy, S; Odvina, CV; Rao, DS; Rao, S; Zerwekh, JE | 1 |
| Blumentals, WA; Cole, RE; Harris, ST; Huang, L; Silverman, SL | 1 |
| Ayogu, N; Bouxsein, ML; Chacko, AT; Rozental, TD; Vazquez, MA | 1 |
| Bachmann, GA; Binkley, N; Derman, RJ; Greenwald, M; Kohles, JD; Martens, MG; Silverman, SL | 1 |
| Möller, G; Ringe, JD | 1 |
| Goss, A; Hughes, T; Kunchur, R; Need, A | 1 |
| Akiyoshi, T; Anami, S; Matsuyama, K; Matzno, S; Nakabayashi, T; Nishiguchi, T | 1 |
| Keel, C; Kraenzlin, CA; Kraenzlin, ME; Meier, C; Müller, B | 1 |
| Asano, S; Itoh, M; Suzuki, A | 1 |
| Abelson, A; Gold, DT; Lange, JL; Ringe, JD; Thomas, T | 1 |
| Bivi, N; Bonetti, A; Clarke, I; Delneri, D; Harrison, R; Hoyle, DC; Moro, L; Ortolani, F; Quadrifoglio, F; Romanello, M; Tell, G | 1 |
| Chandra, M; Go, AS; Gordon, NP; Hui, RL; Hutchinson, M; Lathon, PV; Lo, JC; Martin, D; McCloskey, CA; O'Ryan, FS; Sanchez, G; Selby, JV; Silver, P; Staffa, JA; Willy, M; Yang, J | 1 |
| Borah, B; Chevalier, Y; Gross, G; Lang, T; Quek, E; Stewart, J; Zysset, P | 1 |
| Glickman, G; He, J; Hsiao, A | 1 |
| Allen, MR; Burr, DB; Feher, A; Fuchs, RK; Koivunemi, A; Koivunemi, M; Phipps, RJ; Reinwald, S | 1 |
| Allen, MR; Boskey, AL; Burr, DB; Gourion-Arsiquaud, S; Tang, SY; Vashishth, D | 1 |
| Kim, DY; Kwon, YD; Ohe, JY; Walter, C; Yoo, JY | 1 |
| Dobbins, EK; Duvall, CA; Gates, BJ; Sonnett, TE | 1 |
| Barbier, S; Beard, MK; Chen, E; de Papp, AE; Rosenberg, E; Stovall, DW | 1 |
| Berto, P; Lopatriello, S; Maggi, S; Noale, M | 1 |
| Endo, Y; Funayama, H; Kawamura, H; Kumamoto, H; Kuroishi, T; Oizumi, T; Sasaki, K; Sugawara, S; Takahashi, H; Yamaguchi, K; Yamamoto, M; Yokoyama, M | 1 |
| Henry, C; Jahnke, W | 1 |
| Hosoi, T; Okano, T; Shiraki, M; Shiraki, Y; Tsugawa, N; Yamazaki, Y | 1 |
| Mattos, K; Migliorati, CA; Palazzolo, MJ | 1 |
| Girgis, CM; Seibel, MJ; Sher, D | 1 |
| Aspenberg, P; Fahlgren, A; Schilcher, J | 1 |
| Doschak, MR; Jones, MD; Li, G; Maksymowych, WP; Tran, CW; Zernicke, RF | 1 |
| Baldoni, M; Lauritano, D; Leonida, A; Rossi, G; Vescovi, P | 1 |
| Charle-Crespo, MÁ; Gomes-Carvalho, CS; Guerra-García, MM; Prejigueiro-Santás, A; Puga-Sarmiento, E; Rodríguez-Fernández, JB | 1 |
| Glendenning, P; Inderjeeth, CA; Lee, S | 1 |
| Allen, MR; Burr, DB; Phipps, RJ; Turek, JJ | 1 |
| Blouin, S; Fratzl-Zelman, N; Klaushofer, K; Misof, BM; Paschalis, EP; Roschger, P | 1 |
| Kou, TD; Masud, T; Ralston, SH; Steinbuch, M; Wick-Urban, B | 1 |
| Barrier, A; Descroix, V; Goudot, P; Lescaille, G; Rigolet, A; Ruhin, B | 1 |
| Eisman, JA; Jönsson, B; Kanis, JA; Papaioannou, A; Siris, ES; Ström, O; Tosteson, A | 1 |
| Iba, K; Katahira, G; Takada, J; Yamashita, T; Yoshizaki, T | 1 |
| Alvarez, A; Benedetti, A; Haziza, M; Kremer, R; Trojan, DA; Weiss, DR | 1 |
| Abrams, J; Bhargaval, A; Graff, JJ; Nahleh, Z; Nirmal, K | 1 |
| Pazianas, M | 1 |
| Bliuc, D; Center, JR; Eisman, JA; Nguyen, ND; Nguyen, TV | 1 |
| Chandran, M; Cheen, MH; Kong, MC; Tee, FM; Zhang, RF | 1 |
| Landfeldt, E; Lang, A; Robbins, S; Ström, O | 1 |
| Bhattacharyya, I; Bowers, LM; Cohen, DM; Fitzpatrick, SG; Green, JG; Hinkson, DW; Neuman, AN; Stavropoulos, MF | 1 |
| Guañabens, N; Martínez-Ferrer, A; Monegal, A; Olivares, V; Peris, P; Reyes, R; Torra, M | 1 |
| Ott, SM | 1 |
| Buchinger, B; Gamsjaeger, S; Klaushofer, K; Paschalis, EP; Phipps, R; Zoehrer, R | 1 |
| Chan, SP; Chew, YY; Chua, SS; Lai, PS | 1 |
| Abarca, J; Campbell, HE; Martin, KE; White, TJ; Yu, J | 1 |
| Baskol, M; Bayram, F; Gursoy, S; Kalkan, AO; Karaman, A; Kula, M; Ozbakir, O; Torun, E; Yucesoy, M; Yurci, A | 1 |
| Blake, GM; Eastell, R; Fogelman, I; Frost, ML; Marsden, PK; Moore, AE; Schleyer, PJ; Siddique, M | 1 |
| Landfeldt, E; Ström, O | 1 |
| Amagase, K; Inaba, A; Ishikawa, Y; Murakami, T; Nukui, K; Senta, T; Takeuchi, K | 1 |
| Ebetino, FH; Gamsjaeger, S; Hofstetter, B; Klaushofer, K; Paschalis, EP; Phipps, RJ; Recker, RR | 1 |
| Cooper, C; Cortet, B; Diaz-Curiel, M; Kanis, JA; Lorenc, RS; Reginster, JY; Rizzoli, R | 1 |
| Chan, SP; Chua, SS; Lai, PS | 1 |
| Britton, C; Walsh, J | 1 |
| Abrahamsen, B; Pazianas, M; Russell, RG; Wang, Y | 1 |
| Arias, M; Barros, X; Blasco, M; Campistol, JM; Cases, A; Durán, CE; Torregrosa, JV | 1 |
| Kharazmi, M; Persson, U; Warfvinge, G | 1 |
| Bae, SJ; Kim, BJ; Kim, GS; Kim, HK; Koh, JM; Lee, SH; Lim, KH | 1 |
| Angthong, C; Angthong, W | 1 |
| Abelson, A; Atlan, P; Gold, DT; Horlait, S; Lange, JL; Ringe, JD; Thomas, T | 1 |
| Chen, M; Chen, Y; Chen, Z; Liu, Y; Zhu, Y | 1 |
| Adachi, JD; Becker, DL; Chau, D; Coombes, ME; Goeree, R; Ioannidis, G | 1 |
| Yates, J | 1 |
| Arranz Caso, JA; Dominguez-Mompello, JL; Flores Ballester, E; López Pizarro, V; Ngo Pombe, S; Restoy Lozano, A | 1 |
| Jönsson, B; Kanis, JA; Ström, O | 1 |
| Asahina, I; Hasegawa, T; Ikeda, H; Kobayashi, M; Komatsubara, H; Komori, T; Ri, S; Shibuya, Y; Shigeta, T; Umeda, M; Yoshitomi, I | 1 |
| Dambacher, MA; Dukas, L; Ringe, JD; Von Schacht, E | 1 |
| de Boer, PT; Postma, MJ; van Boven, JF; Vegter, S | 1 |
| Alsarraj, A; El-Serag, HB; Graham, DY; Kramer, JR; Lin, D; Parente, P; Ramsey, D; Rugge, M; Verstovsek, G | 1 |
| Diz, P; Feijoo, JF; García, A; Limeres, J; López-Cedrún, JL; Peñarrocha, M; Sanromán, JF | 1 |
| Huang, J; Kruse, M; Parthan, A; Taylor, D; Viswanathan, HN; Yurgin, N | 1 |
| Fujimoto, Y; Muramatsu, K; Murayama, M; Nakata, E; Nomura, T; Ogane, S; Sekine, R; Shibahara, T; Shibui, T; Uchiyama, T; Watanabe, A; Yakushiji, T; Yamamoto, N | 1 |
| Capaldo, A; Di Somma, C; Gimigliano, F; Iolascon, G; Menditto, E; Orlando, V | 1 |
| Gandhi, S; Modi, A; Sen, S; Siris, ES; Tang, J | 1 |
| Brown, JP; Fahrleitner-Pammer, A; Ferreira, I; Hawkins, F; Ho, PR; Hofbauer, LC; Micaelo, M; Minisola, S; Papaioannou, N; Roux, C; Siddhanti, S; Stone, M; Wagman, RB; Wark, JD; Zillikens, MC | 1 |
| Inoue, D; Konda, T; Shiozaki, M; Yamada, M; Yano, T | 1 |
| Chikazu, D; Hamada, H; Koizumi, T; Matsuo, A; Satomi, T | 1 |
| Beck-Peccoz, P; Cairoli, E; Chiodini, I; Eller-Vainicher, C; Morelli, V; Palmieri, S; Ulivieri, FM; Zhukouskaya, VV | 1 |
| Gopal, GK; Krishnan, SP; Maddern, IL; Tam, KL | 1 |
| Hviid, A; Pasternak, B; Svanström, H | 1 |
| Soen, S | 1 |
| Fadda, V; Maratea, D; Marinai, C; Messori, A; Trippoli, S | 1 |
| Eastell, R; McCloskey, E; Paggiosi, MA; Peel, N; Walsh, JS | 1 |
| Cai, HF; Li, YT; Zhang, ZL | 1 |
| Garellick, G; Landfeldt, E; Ström, O | 1 |
| Akashi, M; Hasegawa, T; Imai, Y; Komori, T; Takeda, D | 1 |
| Ikegami, S; Kamimura, M; Kato, H; Mukaiyama, K; Nakamura, Y; Uchiyama, S | 1 |
| Bonel, E; Del Rio, L; Di Gregorio, S; García, M; Rodriguez-Tolra, J; Winzenrieth, R | 1 |
| Aspenberg, P; Koeppen, V; Michaëlsson, K; Schilcher, J | 1 |
| Furuya, T; Hasegawa, M; Hirabayashi, H; Iwamoto, J; Kumakubo, T; Makita, K; Okano, H; Urano, T | 1 |
| Cankaya, D; Gunay, MC; Ozturk, AM; Tabak, Y | 1 |
| Modi, A; Sajjan, S; Siris, ES; Steve Fan, CP | 1 |
| Eastell, R; Gossiel, F; Jacques, RM; McCloskey, EV; Naylor, KE; Paggiosi, M; Peel, NF; Walsh, JS | 1 |
| Chen, LX; Feng, SQ; Li, YL; Ning, GZ; Zhang, D; Zhang, TS; Zhou, ZR | 1 |
| Di Bonito, M; Ferretti, V; Giampà, E; Nuvoli, G; Paoletti, F; Piazzini, M; Ranieri, M; Tuveri, MA; Vinicola, V | 1 |
| Adami, S; Gatti, D; Rossini, M; Viapiana, O | 1 |
| Ju, JH; Jung, SM; Koh, JH; Kwok, SK; Lee, J; Myong, JP; Park, SH | 1 |
| Eiken, P; Vestergaard, P | 1 |
| Ebina, K; Hashimoto, J; Hirao, M; Kaneshiro, S; Noguchi, T; Yoshikawa, H; Yukioka, M | 1 |
| Adams-Huet, B; Maalouf, NM; Poindexter, JR; Xu, LH | 1 |
| Amin, NL; James, RM; Phillips, R | 1 |
| Cadarette, SM; Jandoc, R; Lévesque, LE; Mamdani, M | 1 |
| Borgström, F; da Silva, JA; Kanis, JA; Lourenço, Ó; Marques, A; Ortsäter, G | 1 |
| Hyodo, K; Kamada, H; Mishima, H; Nishino, T; Nozawa, D; Yamazaki, M | 1 |
| Etminan, M; Guo, M; Maberley, D; Mammo, Z; Matsubara, J | 1 |
| Mészaros, Á; Veszelyné Kotán, E | 2 |
| Chodick, G; Goldshtein, I; Rouach, V; Shamir-Stein, N; Yu, J | 1 |
| Uğurlar, M | 1 |
| Kõks, S; Laius, O; Maasalu, K; Märtson, A | 1 |
| Campbell, F; Davis, S; Gittoes, N; Goka, E; Martyn-St James, M; Rawdin, A; Sadler, S; Sanderson, J; Selby, P; Stevens, J; Stevenson, M; Strong, M; Wong, R | 1 |
| Chen, H; Ma, H; Ma, J; Wang, P; Zhang, H; Zhang, Y; Zhao, X; Zhou, C; Zhu, Y | 1 |
| Greenspan, SL; Nayak, S | 1 |
| Inoue, D; Yamada, M; Yano, T | 1 |
| Albert, SG; Reddy, S | 1 |
| Liel, Y; Plakht, Y; Tailakh, MA | 1 |
| Blouin, S; Klaushofer, K; Lueger, S; Misof, BM; Paschalis, EP; Phipps, R; Recker, RR; Roschger, P | 1 |
| Intorcia, M; Karlsson, L; Mesterton, J; Overbeek, J; Ström, O; Tepie, MF | 1 |
| Classen, K; Lange, U; Müller-Ladner, U; Richter, M | 1 |
| Lozano-Morillo, F; Maroñas-Jiménez, L; Vico-Alonso, C | 1 |
| Inoue, S; Kuroda, T; Shiraki, M; Tanaka, S; Uenishi, K; Urano, F; Urano, T | 1 |
| Bradburn, M; Eastell, R; Gossiel, F; McCloskey, EV; Naylor, KE; Paggiosi, MA; Peel, NFA; Walsh, JS | 1 |
| Belzile, EL; Leclerc, JT; Michou, L; Pelet, S; Simonyan, D; Vaillancourt, F | 1 |
| Abu Tailakh, M; Liel, Y | 1 |
| Adachi, JD; Berger, C; Bliuc, D; Center, JR; Eisman, JA; Geusens, P; Goltzman, D; Hanley, DA; Josse, RG; Kaiser, S; Kovacs, CS; Langsetmo, L; Nguyen, TV; Prior, JC; Tran, T; van den Bergh, J; van Geel, T | 1 |
| Kishino, M; Nakamura, S; Tokushige, K; Yamamoto, K | 1 |
| Hiligsmann, M; Reginster, JY | 1 |
| Chaurand-Lara, J; Facio-Umaña, JA; Mora-Pérez, J; Pacheco-Ruiz, L; Trejo-Campos, JL | 1 |
| Athanasiadis, G; Ban, JK; Burden, AM; Cadarette, SM; Hayes, KN | 1 |
| Adachi, JD; Berger, C; Bliuc, D; Center, JR; Eisman, JA; Geusens, P; Goltzman, D; Hanley, DA; Josse, R; Kaiser, S; Kovacs, CS; Langsetmo, L; Nguyen, TV; Prior, JC; Tran, T; van den Bergh, J; van Geel, T | 1 |
| Adib, G; Adler, RA; Åkesson, KE; Alexander, IM; Amenta, KC; Blank, RD; Brox, WT; Carmody, EE; Chapman-Novakofski, K; Clarke, BL; Cody, KM; Conley, RB; Cooper, C; Crandall, CJ; Dirschl, DR; Eagen, TJ; Elderkin, AL; Fujita, M; Greenspan, SL; Halbout, P; Hochberg, MC; Javaid, M; Jeray, KJ; Kearns, AE; Khosla, S; Kiel, DP; King, T; Koinis, TF; Koontz, JS; Kužma, M; Lindsey, C; Lorentzon, M; Lyritis, GP; Michaud, LB; Miciano, A; Morin, SN; Mujahid, N; Napoli, N; Olenginski, TP; Puzas, JE; Rizou, S; Rosen, CJ; Saag, K; Thompson, E; Tosi, LL; Tracer, H | 1 |
| Iba, K; Sonoda, T; Takada, J; Yamashita, T | 1 |
| Adami, G; Arora, T; Cadarette, SM; Chen, R; Curtis, JR; Daigle, S; Danila, MI; Delzell, E; Foster, J; Jaleel, A; Mudano, A; Saag, KG; Wright, NC; Yun, H | 1 |
| Min, N; Shi, L; Wang, F; Xue, QY | 1 |
| Cui, P; Jia, B; Kong, F; Wang, D | 1 |
| Ebetino, FH; McClung, MR | 1 |
| Ralston, SH | 1 |
| Bouin, M; Nguyen, PV; Ste-Marie, LG | 1 |
| Ballal, P; Duryea, J; Lu, N; Neogi, T; Ratzlaff, C; Sury, M; Zhang, Y | 1 |
| Chen, D; Huang, X; Jin, Z; Liu, Q; Ma, T; Ye, Z | 1 |
| Adams, A; Heidenreich, A; Jakob, T; Kuhr, K; Macherey, S; Monsef, I; Skoetz, N; Tesfamariam, YM | 1 |
| Alam, A; Boolell, M; Gauthier, G; Palacios, S; Thomasius, F; Vekeman, F | 1 |
| Du, D; Gu, M; Jin, L; Xu, J; Yang, Z; Zhang, C; Zhao, S; Zhao, T; Zhao, W; Zheng, L | 1 |
| Brown, KA; Cadarette, SM; Cheung, AM; Hayes, KN; Juurlink, DN; Kim, SA | 1 |
| Brown, JP; Burke, N; Goeree, R; Jobin, M; Johnson, B; Lawrence, D; Stollenwerk, B; Willems, D | 1 |
| Colarossi, G; Driessen, A; Eschweiler, J; Maffulli, N; Migliorini, F; Oliva, F | 1 |
| González Macías, J; Olmos Martínez, JM | 1 |
| Huang, J; Li, P; Li, Y; Wu, X | 1 |
| Cicchiello, S; De Ponte, FS; Lo Giudice, G; Marino, R; Mummolo, S; Nastro Siniscalchi, E; Scozzaro, C; Squillacioti, A | 1 |
| McConnell, M; Shieh, A | 1 |
| Al-Daghri, N; Bock, O; Branco, J; Bruyère, O; Casado, E; Cavalier, E; Cooper, C; Cortet, B; de Wit, M; Fuggle, N; Giusti, A; Halbout, P; Harvey, NC; Hiligsmann, M; Kanis, JA; Kaufman, JM; Kurth, A; Maggi, S; Matijevic, R; Minisola, S; Palacios, S; Radermecker, RP; Reginster, JY; Rizzoli, R; Thomasius, F; Tuzun, S; Veronese, N | 1 |
| Lane, JM; Levin, JE; Nieves, JW; Tutaworn, T; Wang, Z; Yoo, JE | 1 |
| Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T | 2 |
| Ehrenstein, V; Kafatos, G; Neasham, D; O'Kelly, J; Pedersen, AB; Risbo, N | 1 |
| Alves, C; Batel-Marques, F; Donato, A; Mendes, D; Oliveira, T; Penedones, A | 1 |
| Boolell, M; Cortet, B; Eisman, JA; Heroux, J; Ionescu-Ittu, R; Thomasius, F; Vekeman, F | 1 |
| Gates, M; Hartling, L; Nuspl, M; Pillay, J; Vandermeer, B; Wingert, A | 1 |
| Amigues, C; Breuil, V; Drici, MD; Fresse, A; Gauthier, S; Roux, CH; Vieillard, MH | 1 |
| Chen, Y; Huang, Y; Xiao, Y | 1 |
| Arístegui, I; Boolell, M; Casado, E; Rosas, J; Rubio-Rodríguez, D; Rubio-Terrés, C | 1 |
119 review(s) available for alendronate and risedronic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Bisphosphonates, Old Friends of Bones and New Trends in Clinics.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Drug Compounding; Drug Delivery Systems; Humans | 2021 |
Bisphosphonate therapy.
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoclasts; Osteoporosis; Osteoporosis, Postmenopausal; Pamidronate; Risedronic Acid | 1997 |
Osteoporosis: diagnosis, prevention, and treatment of established disease.
Topics: Age Factors; Aged; Alendronate; Calcitonin; Calcium Channel Blockers; Calcium, Dietary; Dietary Supplements; Drug Therapy, Combination; Estrogens; Etidronic Acid; Exercise; Female; Hormone Replacement Therapy; Humans; Male; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Vitamin D | 1999 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2000 |
Prevention and treatment of osteoporosis.
Topics: Accidental Falls; Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Calcitonin; Calcium Channel Blockers; Calcium, Dietary; Case-Control Studies; Cohort Studies; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis; Physical Exertion; Postmenopause; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Vitamin D | 2000 |
Gastroenterologists and choosing the right bisphosphonate.
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Gastroenterology; Glucocorticoids; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid | 2000 |
[Effect of anti-osteoporosis agents on the incidence of vertebral fractures].
Topics: Alendronate; Bone Density; Calcitonin; Calcium Channel Blockers; Densitometry; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Osteoporosis, Postmenopausal; Postmenopause; Radiography; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Injuries; Spine | 2000 |
Osteoporosis: which current treatments reduce fracture risk?
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Calcium Channel Blockers; Estrogen Replacement Therapy; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators | 2000 |
Bisphosphonates in the treatment of osteoporosis. Principles and efficacy.
Topics: Administration, Oral; Alendronate; Animals; Bone and Bones; Bone Density; Calcium Channel Blockers; Controlled Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Female; Hip Fractures; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Pamidronate; Papio; Prospective Studies; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Time Factors | 2000 |
Treatment of osteoporosis with bisphosphonates.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Pamidronate; Risedronic Acid | 2001 |
Evidence-based medicine: putting theory into practice.
Topics: Alendronate; Calcium Channel Blockers; Estrogen Replacement Therapy; Etidronic Acid; Evidence-Based Medicine; Female; Humans; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Research Design; Risedronic Acid; State Medicine; Treatment Outcome; United Kingdom | 2001 |
Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance symposium. Biannual Foothills Meeting on Osteoporosis, Calgary, Alberta, Canada, September 9-10, 2000.
Topics: Alendronate; Alkaline Phosphatase; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Humans; Osteitis Deformans; Practice Guidelines as Topic; Risedronic Acid; Time Factors | 2001 |
[Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures].
Topics: Age Factors; Aged; Alendronate; Bone Density; Calcium Channel Blockers; Diphosphonates; Etidronic Acid; Female; Hip Fractures; Humans; Lumbar Vertebrae; Multicenter Studies as Topic; Netherlands; Osteoporosis, Postmenopausal; Prognosis; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures | 2001 |
Pharmacologic therapy for the treatment and prevention of osteoporosis.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Patient Compliance; Patient Selection; Primary Prevention; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome | 2001 |
Bisphosphonates for osteoporosis.
Topics: Aged; Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid | 2001 |
Risedronate: a new oral bisphosphonate.
Topics: Administration, Oral; Alendronate; Calcium Channel Blockers; Diphosphonates; Etidronic Acid; Female; Humans; Male; Osteitis Deformans; Osteoporosis, Postmenopausal; Risedronic Acid | 2001 |
Role of alendronate and risedronate in preventing and treating osteoporosis.
Topics: Alendronate; Cost-Benefit Analysis; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Risedronic Acid; United States | 2001 |
[Alternatives to hormonal treatment for the prevention of postmenopausal osteoporosis: the bisphosphonates].
Topics: Aging; Alendronate; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid | 2001 |
The underuse of therapy in the secondary prevention of hip fractures.
Topics: Accidental Falls; Alendronate; Calcium; Estrogens; Etidronic Acid; Hip Fractures; Hip Prosthesis; Humans; Parathyroid Hormone; Risedronic Acid; Risk Factors; Vitamin D | 2002 |
Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity.
Topics: Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; Digestive System; Drug Interactions; Endoscopy, Gastrointestinal; Etidronic Acid; Gastrointestinal Diseases; Humans; Risedronic Acid | 2002 |
What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates.
Topics: Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Digestive System; Diphosphonates; Drug Interactions; Drug Tolerance; Esophagitis; Etidronic Acid; Gastric Mucosa; Humans; Irritants; Risedronic Acid; Safety | 2002 |
Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review.
Topics: Alendronate; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Risedronic Acid; Time | 2002 |
Bisphosphonates.
Topics: Alendronate; Diphosphonates; Drug Administration Schedule; Estrogen Replacement Therapy; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Risedronic Acid | 2002 |
Osteoporosis in elderly: prevention and treatment.
Topics: Aged; Alendronate; Etidronic Acid; Exercise; Female; Fractures, Bone; Hormone Replacement Therapy; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Spinal Fractures | 2002 |
Risedronate prevents hip fractures, but who should get therapy?
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcium Channel Blockers; Etidronic Acid; Female; Hip Fractures; Humans; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; United States | 2002 |
[Osteoporosis].
Topics: Alendronate; Bone Density; Drug Therapy, Combination; Estrogen Replacement Therapy; Etidronic Acid; Evidence-Based Medicine; Female; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid | 2002 |
[Treatment of osteoporosis provided from the orthopaedic surgeon's standpoint].
Topics: Alendronate; Etidronic Acid; Fractures, Bone; Humans; Osteoporosis; Risedronic Acid | 2003 |
[Osteoporosis in men].
Topics: Alendronate; Androgens; Calcium Channel Blockers; Diagnosis, Differential; Etidronic Acid; Fractures, Bone; Humans; Hydroxycholecalciferols; Hypogonadism; Male; Osteoporosis; Primary Prevention; Risedronic Acid; Risk Factors | 2003 |
Canadian consensus on osteoporosis. Preventing osteoporosis among postmenopausal women.
Topics: Aged; Alendronate; Calcium Channel Blockers; Canada; Estrogen Replacement Therapy; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Primary Prevention; Risedronic Acid; Risk Assessment | 2003 |
Identifying the osteopenic patient and preventing worsening of the disease.
Topics: Alendronate; Body Mass Index; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Calcitonin; Estrogen Replacement Therapy; Estrogens; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis, Postmenopausal; Patient Education as Topic; Progestins; Risedronic Acid; Risk Factors; United States | 2003 |
Prevention and treatment of osteoporosis.
Topics: Aged; Alendronate; Calcitonin; Calcium; Dietary Supplements; Estrogen Replacement Therapy; Etidronic Acid; Exercise; Female; Humans; Middle Aged; Osteoporosis; Risedronic Acid; Selective Estrogen Receptor Modulators; Vitamin D | 2002 |
Bisphosphonates: new indications and methods of administration.
Topics: Alendronate; Animals; Diphosphonates; Etidronic Acid; Fractures, Spontaneous; Humans; Imidazoles; Osteoporosis; Risedronic Acid; Structure-Activity Relationship; Zoledronic Acid | 2003 |
Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Topics: Aged; Alendronate; Calcium Channel Blockers; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Prevalence; Risedronic Acid; Spinal Fractures | 2003 |
An update on bisphosphonates.
Topics: Alendronate; Bone Density; Diphosphonates; Drug Therapy, Combination; Estrogens; Etidronic Acid; Humans; Osteoclasts; Osteoporosis; Risedronic Acid; Treatment Outcome | 2004 |
An approach to postmenopausal osteoporosis treatment: a case study review.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Exercise Therapy; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators; Smoking; Vitamin D | 2003 |
Osteoporosis management in the new millennium.
Topics: Alendronate; Bone Density; Calcitonin; Calcium; Estrogens; Etidronic Acid; Exercise; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid | 2003 |
[New guideline for the treatment of osteoporosis].
Topics: Alendronate; Calcitonin; Calcium; Estrogen Replacement Therapy; Etidronic Acid; Evidence-Based Medicine; Humans; Meta-Analysis as Topic; Osteoporosis; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators; Vitamin D; Vitamin K 2 | 2004 |
[Combination therapy of bisphosphonate and estrogen for osteoporosis].
Topics: Alendronate; Bone Density; Diphosphonates; Drug Therapy, Combination; Estrogens; Etidronic Acid; Femur Neck; Humans; Osteoporosis; Risedronic Acid; Spine | 2004 |
Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer.
Topics: Absorptiometry, Photon; Alendronate; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Drug Therapy, Combination; Estrogens; Etidronic Acid; Female; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Quality of Life; Risedronic Acid; Risk Factors; Treatment Outcome; Vitamin D; Zoledronic Acid | 2004 |
Prevention of glucocorticoid-induced osteoporosis.
Topics: Alendronate; Algorithms; Calcitonin; Diphosphonates; Etidronic Acid; Glucocorticoids; Humans; Osteoporosis; Parathyroid Hormone; Risedronic Acid | 2004 |
Pharmacologic prevention of osteoporotic fractures.
Topics: Aged; Alendronate; Bone Density; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators | 2004 |
Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations.
Topics: Alendronate; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Risedronic Acid | 2004 |
Treating osteoporosis in post-menopausal women: a case approach.
Topics: Aged; Alendronate; Densitometry; Diphosphonates; Etidronic Acid; Female; Humans; Mass Screening; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome | 2004 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Alendronate; Anabolic Agents; Bone Resorption; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Fractures, Bone; Glucocorticoids; Humans; Ibandronic Acid; Osteoporosis; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Teriparatide | 2005 |
[Pharmacological treatment of osteitis deformans (Paget's bone disease)].
Topics: Alendronate; Analgesics, Non-Narcotic; Antimetabolites; Calcitonin; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Osteitis Deformans; Pamidronate; Radionuclide Imaging; Risedronic Acid | 2005 |
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Topics: Age Factors; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Cost-Benefit Analysis; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Teriparatide | 2005 |
The use of bisphosphonates in the treatment of osteoporosis.
Topics: Alendronate; Bone Density; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Male; Osteogenesis; Osteoporosis, Postmenopausal; Risedronic Acid | 2005 |
Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Fractures, Bone; Humans; Middle Aged; Organometallic Compounds; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Thiophenes | 2005 |
Use of highly potent bisphosphonates in the treatment of osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Remodeling; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Prognosis; Randomized Controlled Trials as Topic; Risedronic Acid; Severity of Illness Index; Treatment Outcome | 2003 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Aged; Alendronate; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2004 |
Glucocorticoid-induced osteoporosis: treatment options and guidelines.
Topics: Alendronate; Bone Density; Bone Resorption; Diphosphonates; Etidronic Acid; Exercise; Female; Fractures, Bone; Glucocorticoids; Guideline Adherence; Humans; Male; Osteogenesis; Osteoporosis; Parathyroid Hormone; Practice Guidelines as Topic; Risedronic Acid | 2005 |
Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis.
Topics: Administration, Oral; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Risedronic Acid | 2005 |
Review of treatment modalities for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Combined Modality Therapy; Diet; Dietary Supplements; Diphosphonates; Etidronic Acid; Exercise; Female; Fish Oils; Hip Fractures; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Teriparatide; Vitamin D; Vitamin D Deficiency | 2005 |
Prevention and treatment of glucocorticoid-induced osteoporosis in 2005.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Glucocorticoids; Humans; Osteoporosis; Risedronic Acid; Risk Factors | 2005 |
Strategies for the prevention and treatment of osteoporosis during early postmenopause.
Topics: Accidental Falls; Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Exercise; Female; Humans; Ibandronic Acid; Life Style; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Perimenopause; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators; Smoking; Vitamin D | 2006 |
[Application of anti-resorptive drugs for the treatment of osteoporosis].
Topics: Aged; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Risedronic Acid | 2006 |
Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Fractures, Bone; Gastrointestinal Diseases; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Risedronic Acid | 2006 |
Drug injury in the upper gastrointestinal tract: effects of alendronate.
Topics: Alendronate; Bone Density Conservation Agents; Duodenum; Etidronic Acid; Gastric Mucosa; Humans; Models, Animal; Risedronic Acid | 2006 |
Preventing osteoporosis-related fractures: an overview.
Topics: Absorptiometry, Photon; Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Calcitonin; Calcium, Dietary; Dietary Supplements; Diphosphonates; Etidronic Acid; Exercise; Female; Fractures, Bone; Humans; Ibandronic Acid; Motor Activity; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Risedronic Acid; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Teriparatide; United States; Vitamin D | 2006 |
Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Risedronic Acid; Treatment Outcome | 2006 |
Long-term experience with alendronate in the treatment of osteoporosis.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcitonin; Drug Administration Schedule; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid | 2006 |
Drug insight: Bisphosphonates for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Risedronic Acid | 2006 |
Fracture prevention in postmenopausal women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Hormone Replacement Therapy; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Pamidronate; Parathyroid Hormone; Risedronic Acid; Selective Estrogen Receptor Modulators; Vitamin D | 2006 |
Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Osteonecrosis; Osteoporosis; Risedronic Acid; Zoledronic Acid | 2006 |
How long should patients take medications for postmenopausal osteoporosis?
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Drug Administration Schedule; Drug Monitoring; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Assessment; Teriparatide; Thiophenes; Time Factors; Treatment Outcome | 2007 |
Bisphosphonates.
Topics: Alendronate; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2006 |
[Secondary osteoporosis. Evidence of treatment efficacy in patients with glucocorticoid-induced osteoporosis].
Topics: Alendronate; Bone Density Conservation Agents; Calcitonin; Cholecalciferol; Etidronic Acid; Evidence-Based Medicine; Glucocorticoids; Humans; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Vitamin K 2 | 2007 |
Is cortical bone hip? What determines cortical bone properties?
Topics: Alendronate; Bone and Bones; Bone Density; Bone Remodeling; Etidronic Acid; Fractures, Spontaneous; Hip; Hip Fractures; Humans; Osteoporosis; Peptide Fragments; RANK Ligand; Risedronic Acid; Teriparatide | 2007 |
Osteochemonecrosis of jaws and bisphosphonates.
Topics: Alendronate; Bone Density Conservation Agents; Etidronic Acid; Humans; Jaw; Osteonecrosis; Osteoporosis; Risedronic Acid; Risk Factors | 2007 |
Pharmacological treatment of osteoporosis for people over 70.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Parathyroid Hormone; Risedronic Acid; Thiophenes; Vitamin D | 2007 |
Safety considerations with bisphosphonates for the treatment of osteoporosis.
Topics: Acute-Phase Reaction; Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Ibandronic Acid; Injections, Intravenous; Jaw Diseases; Osteonecrosis; Osteoporosis, Postmenopausal; Renal Insufficiency; Risedronic Acid | 2007 |
[Osteoporosis in the patients with rheumatoid arthritis (3) : the efficacy and the selection of the osteoporosis therapeutic drug].
Topics: Alendronate; Arthritis, Rheumatoid; Bone Density Conservation Agents; Etidronic Acid; Humans; Osteoporosis; Risedronic Acid | 2007 |
Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Etidronic Acid; Female; Glucocorticoids; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; RANK Ligand; Risedronic Acid | 2007 |
Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures.
Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Clodronic Acid; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Risedronic Acid; Selective Estrogen Receptor Modulators; Teriparatide; Thiophenes; Vitamin D | 2007 |
[FACT study].
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidronic Acid; Evidence-Based Medicine; Female; Femur; Fractures, Bone; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risedronic Acid | 2007 |
[Bisphosphonates for osteoporosis].
Topics: Alendronate; Bone Density Conservation Agents; Contraindications; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Humans; Osteoporosis; Risedronic Acid | 2007 |
[Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Clinical Trials as Topic; Double-Blind Method; Etidronic Acid; Gastrointestinal Diseases; Humans; Lumbar Vertebrae; Osteoporosis; Patient Compliance; Risedronic Acid; Spinal Fractures | 2007 |
Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Male; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Spinal Fractures; Zoledronic Acid | 2008 |
Paget disease of bone: therapeutic options.
Topics: Alendronate; Alkaline Phosphatase; Anti-Inflammatory Agents; Diphosphonates; Etidronic Acid; Humans; Osteitis Deformans; Pamidronate; Retreatment; Risedronic Acid; Treatment Outcome | 2008 |
[New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Patient Compliance; Risedronic Acid; Zoledronic Acid | 2009 |
Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
Topics: Alendronate; Bone Density Conservation Agents; Etidronic Acid; Fractures, Bone; Humans; Organometallic Compounds; Osteoporosis; Risedronic Acid; Teriparatide; Thiophenes | 2009 |
Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2009 |
Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fracture Healing; Fractures, Bone; Humans; Jaw Diseases; Middle Aged; Osteonecrosis; Osteoporosis, Postmenopausal; Pamidronate; Risedronic Acid | 2009 |
[Biochemical markers of bone turnover. New aspect. Biochemical markers of bone turnover in long term treatment with bisphosphonate].
Topics: Alendronate; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Etidronic Acid; Fractures, Spontaneous; Humans; Osteoporosis; Risedronic Acid; Time Factors | 2009 |
Review of osteoporosis pharmacotherapy for geriatric patients.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Economics, Pharmaceutical; Etidronic Acid; Exercise; Female; Humans; Ibandronic Acid; Life Style; Male; Osteonecrosis; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Vitamin D | 2009 |
Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Middle Aged; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Patient Compliance; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Treatment Outcome | 2011 |
Osteonecrosis of the jaw and the role of macrophages.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Imidazoles; Indoles; Jaw Diseases; Macrophages; Magnetic Resonance Imaging; Mevalonic Acid; Monocytes; Mouth Mucosa; Osteoclasts; Osteomyelitis; Osteonecrosis; Positron-Emission Tomography; Pyrroles; Radiography, Panoramic; RANK Ligand; Risedronic Acid; Risk Factors; Signal Transduction; Sunitinib; Tomography, X-Ray Computed; Vitamin D; Zoledronic Acid | 2011 |
What is the optimal duration of bisphosphonate therapy?
Topics: Alendronate; Biomarkers; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Femoral Fractures; Fractures, Bone; Humans; Osteoporosis; Risedronic Acid; Risk Factors; Time Factors | 2011 |
Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF).
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Risedronic Acid; Thiophenes; Vitamin D | 2012 |
A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Spine | 2013 |
[Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces].
Topics: Actinomyces; Actinomycosis; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Combined Modality Therapy; Diphosphonates; Disease Susceptibility; Etidronic Acid; Female; Humans; Imidazoles; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Models, Biological; Neoplasms; Osteitis; Osteoporosis; Retrospective Studies; Risedronic Acid; Zoledronic Acid | 2012 |
[Combination of alendronate plus alfacalcidol in the treatment of osteoporosis. Rationale, preclinical data and clinical evidence].
Topics: Aged; Alendronate; Animals; Bone Density; Disease Models, Animal; Drug Combinations; Drug Interactions; Etidronic Acid; Evidence-Based Medicine; Female; Humans; Hydroxycholecalciferols; Long-Term Care; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Rats; Risedronic Acid | 2012 |
[Glucocorticoid and bone].
Topics: Administration, Ophthalmic; Adult; Aged; Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Glucocorticoids; Humans; Male; Mice; Middle Aged; Osteogenesis; Osteoporosis; Practice Guidelines as Topic; Prednisolone; Risedronic Acid; Risk; Teriparatide | 2014 |
Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Female; Humans; Ibandronic Acid; Incidence; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Therapeutic Equivalency | 2014 |
Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized controlled trials.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Etidronic Acid; Female; Fracture Healing; Humans; Imidazoles; Male; Middle Aged; Randomized Controlled Trials as Topic; Risedronic Acid; Treatment Outcome; Zoledronic Acid | 2015 |
Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Hydroxycholecalciferols; Ibandronic Acid; Imidazoles; Lumbar Vertebrae; Osteoporosis; Parathyroid Hormone; Risedronic Acid; Teriparatide; Thiophenes; Zoledronic Acid | 2015 |
The use of bisphosphonates in women: when to use and when to stop.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Factors; Time Factors; Zoledronic Acid | 2015 |
Treatment of osteoporosis after alendronate or risedronate.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substitution; Female; Humans; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Teriparatide; Thiophenes; Zoledronic Acid | 2016 |
QUESTION 1: Should we be using bisphosphonates for osteonecrosis complicating childhood acute lymphoblastic leukaemia?
Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteonecrosis; Pain; Pamidronate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risedronic Acid | 2016 |
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I].
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Hungary; Ibandronic Acid; Imidazoles; Osteoporosis; Pamidronate; Risedronic Acid; Zoledronic Acid | 2016 |
A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
Topics: Alendronate; Bone Density Conservation Agents; Cost of Illness; Cost-Benefit Analysis; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Models, Econometric; Osteoporotic Fractures; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Social Work; State Medicine; United Kingdom; Zoledronic Acid | 2016 |
Efficacy and safety of medical therapy for low bone mineral density in patients with Crohn disease: A systematic review with network meta-analysis.
Topics: Alendronate; Bayes Theorem; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Crohn Disease; Diphosphonates; Humans; Imidazoles; Network Meta-Analysis; Risedronic Acid; Sodium Fluoride; Zoledronic Acid | 2017 |
Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis.
Topics: Alendronate; Bone Density Conservation Agents; Calcitonin; Denosumab; Humans; Male; Osteoporosis; Osteoporotic Fractures; Risedronic Acid; Spinal Fractures | 2017 |
CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
Topics: Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Diphosphonates; Drug Costs; Female; Hip Fractures; Humans; Imidazoles; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Teriparatide; Zoledronic Acid | 2017 |
Bisphosphonates for Secondary Prevention of Osteoporotic Fractures: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Topics: Aged; Alendronate; Bayes Theorem; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Male; Middle Aged; Network Meta-Analysis; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risedronic Acid; Secondary Prevention; Zoledronic Acid | 2019 |
History of risedronate.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Male; Osteoporosis, Postmenopausal; Risedronic Acid | 2020 |
Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Case-Control Studies; Collagen Type I; Creatinine; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Tartrate-Resistant Acid Phosphatase; Treatment Outcome; Vitamin D | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Denosumab; Diphosphonates; Etidronic Acid; Humans; Male; Network Meta-Analysis; Pamidronate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Zoledronic Acid | 2020 |
Effect of bisphosphonate on hip fracture in patients with osteoporosis or osteopenia according to age: a meta-analysis and systematic review.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Hip Fractures; Humans; Middle Aged; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2022 |
Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis.
Topics: Adrenal Cortex Hormones; Alendronate; Bayes Theorem; Bone Density Conservation Agents; Denosumab; Etidronic Acid; Glucocorticoids; Humans; Network Meta-Analysis; Osteoporosis; Risedronic Acid; Zoledronic Acid | 2022 |
Aminobisphosphonates: Reconsideration 25 years after their approval for the treatment of osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Hydroxyapatites; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Selective Estrogen Receptor Modulators; Zoledronic Acid | 2022 |
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis.
Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Male; Network Meta-Analysis; Osteoporosis; Risedronic Acid; Spinal Fractures; Zoledronic Acid | 2022 |
Polypharmacy in Osteoporosis Treatment.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis; Osteoporotic Fractures; Polypharmacy; Risedronic Acid; Teriparatide; Zoledronic Acid | 2022 |
Novel formulations of oral bisphosphonates in the treatment of osteoporosis.
Topics: Alendronate; Diphosphonates; Fractures, Bone; Humans; Osteoporosis; Risedronic Acid | 2022 |
The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Hormones; Humans; Ibandronic Acid; Male; Neoplasms; Network Meta-Analysis; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2023 |
Ibandronate in the Prevention of Vertebral and Nonvertebral Osteoporotic Fractures: A Systematic Review of Experimental and Observational Studies.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Observational Studies as Topic; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid | 2023 |
Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Topics: Adult; Alendronate; Canada; Denosumab; Diphosphonates; Female; Hip Fractures; Humans; Male; Middle Aged; Osteoporotic Fractures; Primary Health Care; Primary Prevention; Risedronic Acid; Systematic Reviews as Topic; Zoledronic Acid | 2023 |
The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome | 2023 |
44 trial(s) available for alendronate and risedronic acid
| Article | Year |
|---|---|
Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women.
Topics: Adult; Alendronate; Duodenoscopy; Duodenum; Endoscopy; Esophagoscopy; Esophagus; Etidronic Acid; Female; Gastroscopy; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Single-Blind Method; Stomach; Stomach Ulcer | 2000 |
An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae.
Topics: Aged; Aged, 80 and over; Alendronate; Calcium Channel Blockers; Double-Blind Method; Endoscopy, Gastrointestinal; Esophagoscopy; Etidronic Acid; Female; Gastric Mucosa; Humans; Intestinal Mucosa; Male; Middle Aged; Risedronic Acid; Time Factors | 2000 |
Tolerability of risedronate in postmenopausal women intolerant of alendronate.
Topics: Alendronate; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Dropouts; Postmenopause; Risedronic Acid; Treatment Outcome | 2001 |
14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status.
Topics: Aged; Alendronate; Analysis of Variance; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Female; Follow-Up Studies; Gastric Mucosa; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Middle Aged; Osteoporosis, Postmenopausal; Probability; Reference Values; Risedronic Acid; Risk Assessment; Single-Blind Method; Stomach Ulcer; Treatment Outcome | 2002 |
Risedronate prevents hip fractures, but who should get therapy?
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcium Channel Blockers; Etidronic Acid; Female; Hip Fractures; Humans; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; United States | 2002 |
Role of gastric mucosal and gastric juice cytokine concentrations in development of bisphosphonate damage to gastric mucosa.
Topics: Administration, Oral; Aged; Alendronate; Biomarkers; Biopsy, Needle; Cytokines; Dinoprostone; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Female; Gastric Juice; Gastric Mucosa; Gastroscopy; Humans; Interleukin-1; Interleukin-13; Interleukin-8; Middle Aged; Postmenopause; Reference Values; Risedronic Acid; Sensitivity and Specificity; Single-Blind Method | 2003 |
Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study.
Topics: Aged; Aged, 80 and over; Alendronate; Analysis of Variance; Bone Density; Bone Resorption; Calcium Channel Blockers; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid | 2003 |
Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
Topics: Aged; Alendronate; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation Agents; Calcium; Creatinine; Double-Blind Method; Etidronic Acid; Female; Humans; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Risedronic Acid | 2006 |
Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
Topics: Aged; Alendronate; Biomarkers; Bone Remodeling; Calcium Channel Blockers; Diphosphonates; Double-Blind Method; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; United States | 2005 |
Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Resorption; Calcium Channel Blockers; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Humans; Osteoporosis; Postmenopause; Risedronic Acid; Treatment Outcome | 2004 |
Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study.
Topics: Alendronate; Alveolar Bone Loss; Analysis of Variance; Chemotherapy, Adjuvant; Dental Scaling; Diphosphonates; Double-Blind Method; Etidronic Acid; Female; Fractals; Humans; Male; Middle Aged; Periodontal Index; Periodontitis; Radiography; Risedronic Acid; Statistics, Nonparametric | 2005 |
Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Collagen Type I; Etidronic Acid; Female; Hip; Humans; Osteocalcin; Osteoporosis; Osteoprotegerin; Postmenopause; Prospective Studies; RANK Ligand; Risedronic Acid | 2006 |
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years.
Topics: Aged; Alendronate; Bone Density; Bone Remodeling; Double-Blind Method; Etidronic Acid; Female; Femur; Femur Neck; Fractures, Bone; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Treatment Outcome | 2006 |
Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
Topics: Aged; Alendronate; Bone Density; Bone Remodeling; Double-Blind Method; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid | 2006 |
Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women.
Topics: Aged; Alendronate; Asian People; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Patient Satisfaction; Postmenopause; Raloxifene Hydrochloride; Risedronic Acid; Surveys and Questionnaires | 2007 |
Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Collagen Type I; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Factors | 2007 |
The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; C-Reactive Protein; Calcium; Etidronic Acid; Female; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Osteoporosis, Postmenopausal; Phosphorus; Raloxifene Hydrochloride; Risedronic Acid; Uric Acid | 2007 |
Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study.
Topics: Aged; Alendronate; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Etidronic Acid; Family Practice; Female; Fractures, Bone; Humans; Incidence; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Osteoporosis, Postmenopausal; Prednisolone; Pruritus; Retrospective Studies; Risedronic Acid; Time Factors | 2008 |
A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Double-Blind Method; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Treatment Outcome | 2008 |
Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cross-Over Studies; Drugs, Generic; Esophagus; Etidronic Acid; Female; Gastrointestinal Transit; Humans; Middle Aged; Posture; Radionuclide Imaging; Radiopharmaceuticals; Risedronic Acid; Single-Blind Method; Sodium Pertechnetate Tc 99m; Tablets | 2008 |
Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients.
Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Asian People; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Collagen Type I; Etidronic Acid; Female; Humans; Osteogenesis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Peptides; Prospective Studies; Risedronic Acid | 2008 |
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.
Topics: Aged; Aged, 80 and over; Alendronate; Algorithms; Anabolic Agents; Bone Density Conservation Agents; Bone Remodeling; Chemotherapy, Adjuvant; Drug Resistance; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Teriparatide; Time Factors; Treatment Outcome | 2008 |
Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.
Topics: Aged; Aged, 80 and over; Alendronate; Area Under Curve; Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Chelating Agents; Collagen Type I; Edetic Acid; Etidronic Acid; Female; Humans; Hypocalcemia; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Peptides; Raloxifene Hydrochloride; Risedronic Acid | 2009 |
Comparison of the analgesic effects of bisphosphonates: etidronate, alendronate and risedronate by electroalgometry utilizing the fall of skin impedance.
Topics: Aged; Alendronate; Analgesics; Bone and Bones; Diphosphonates; Electric Impedance; Etidronic Acid; Exercise; Female; Humans; Pain Measurement; Patient Dropouts; Risedronic Acid; Skin | 2009 |
Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Gastroesophageal Reflux; Heartburn; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Patient Satisfaction; Risedronic Acid | 2009 |
Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density Conservation Agents; Chronic Disease; Collagen Type I; Diphosphonates; Etidronic Acid; Female; Humans; Immunocompromised Host; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Osteoporosis; Peptides; Predictive Value of Tests; Risedronic Acid; Risk Factors; Sex Factors; Tooth Extraction | 2009 |
Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice.
Topics: Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Regeneration; Bone Resorption; Collagen Type I; Diphosphonates; Drug Interactions; Etidronic Acid; Female; Humans; Isoenzymes; Male; Middle Aged; Organ Specificity; Osteocalcin; Osteoporosis; Peptides; Risedronic Acid; Teriparatide; Time Factors | 2010 |
Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
Topics: Aged; Alendronate; Biomechanical Phenomena; Bone Density Conservation Agents; Etidronic Acid; Female; Finite Element Analysis; Humans; Middle Aged; Osteoporosis; Risedronic Acid; Teriparatide; Tomography, X-Ray Computed | 2010 |
Response to oral bisphosphonates in subgroups of younger and older postmenopausal women.
Topics: Adult; Age Factors; Aged; Alendronate; Analysis of Variance; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Femur; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid | 2010 |
Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcification, Physiologic; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ilium; Osteoporosis, Postmenopausal; Risedronic Acid; Teriparatide; Treatment Outcome | 2010 |
Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
Topics: Alendronate; Biomarkers, Pharmacological; Bone and Bones; Bone Density; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Etidronic Acid; Female; Hip; Humans; Medication Adherence; Menopause; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Pharmaceutical Services; Postmenopause; Risedronic Acid; Sample Size; Time Factors; Treatment Outcome | 2011 |
Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease.
Topics: Absorptiometry, Photon; Adult; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitonin; Chronic Disease; Etidronic Acid; Female; Hepatitis, Viral, Human; Humans; Male; Middle Aged; Osteoporosis; Prospective Studies; Risedronic Acid; Treatment Outcome; Vitamin D | 2011 |
Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Etidronic Acid; Female; Femur; Fluorodeoxyglucose F18; Hip; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Positron-Emission Tomography; Radiopharmaceuticals; Risedronic Acid; Treatment Outcome | 2012 |
Effects of alendronate and risedronate on bone material properties in actively forming trabecular bone surfaces.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Cross-Sectional Studies; Etidronic Acid; Female; Humans; Risedronic Acid; Spectrum Analysis, Raman; Time Factors | 2012 |
Pharmaceutical care issues encountered by post-menopausal osteoporotic women prescribed bisphosphonates.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Health Knowledge, Attitudes, Practice; Humans; Malaysia; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Outcome Assessment, Health Care; Patient Satisfaction; Pharmaceutical Services; Quality of Life; Risedronic Acid | 2012 |
Successful treatment of calcific uraemic arteriolopathy with bisphosphonates.
Topics: Aged; Alendronate; Alkaline Phosphatase; Arterioles; Calciphylaxis; Calcium; Comorbidity; Diphosphonates; Disease Progression; Etidronic Acid; Female; Humans; Hyperparathyroidism, Secondary; Ibandronic Acid; Kidney Transplantation; Male; Middle Aged; Parathyroid Hormone; Parathyroidectomy; Phosphates; Prospective Studies; Renal Dialysis; Risedronic Acid; Skin; Uremia | 2012 |
Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Topics: Aged; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Collagen Type I; Demography; Denosumab; Etidronic Acid; Female; Humans; Medication Adherence; Osteoporosis, Postmenopausal; Peptides; Risedronic Acid; Treatment Outcome | 2014 |
Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Hip Joint; Humans; Ibandronic Acid; Lower Extremity; Lumbar Vertebrae; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Upper Extremity | 2014 |
Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO).
Topics: Aged; Aged, 80 and over; Alendronate; Cross-Over Studies; Demography; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Patient Preference; Risedronic Acid | 2016 |
Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Premenopause; Reference Values; Risedronic Acid; Treatment Outcome | 2016 |
Baseline mineralizing surface determines the magnitude of the bisphosphonate effect on cortical bone mineralization in postmenopausal osteoporotic patients.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcification, Physiologic; Diphosphonates; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid | 2017 |
Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Drug Administration Schedule; Female; Hip Joint; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Withholding Treatment | 2018 |
Prevalence and Characteristics of Atypical Periprosthetic Femoral Fractures.
Topics: Aged; Aged, 80 and over; Alendronate; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Female; Femoral Fractures; Hip Prosthesis; Humans; Knee Prosthesis; Male; Middle Aged; Periprosthetic Fractures; Prevalence; Retrospective Studies; Risedronic Acid; Risk Factors | 2019 |
Reduced Bone Loss Is Associated With Reduced Mortality Risk in Subjects Exposed to Nitrogen Bisphosphonates: A Mediation Analysis.
Topics: Aged; Alendronate; Bone Density; Disease-Free Survival; Female; Humans; Male; Middle Aged; Osteoporosis; Risedronic Acid; Risk Factors; Survival Rate | 2019 |
265 other study(ies) available for alendronate and risedronic acid
| Article | Year |
|---|---|
Bisphosphonates derived from fatty acids are potent growth inhibitors of Trypanosoma cruzi.
Topics: Animals; Bone Resorption; Diphosphonates; Fatty Acids; Humans; Inhibitory Concentration 50; Parasitic Sensitivity Tests; Trypanocidal Agents; Trypanosoma cruzi; United States; United States Food and Drug Administration | 2001 |
Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy.
Topics: Animals; Antiprotozoal Agents; Chlorocebus aethiops; Diphosphonates; Leishmania donovani; Plasmodium falciparum; Structure-Activity Relationship; Toxoplasma; Trypanosoma brucei brucei; Trypanosoma cruzi; Vero Cells | 2001 |
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents.
Topics: Alkyl and Aryl Transferases; Antiparasitic Agents; Bone Resorption; Diphosphonates; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Models, Molecular; Organophosphates; Quantitative Structure-Activity Relationship; Recombinant Proteins | 2002 |
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
Topics: Alkyl and Aryl Transferases; Animals; Bone Resorption; Crystallography, X-Ray; Dictyostelium; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Inhibitory Concentration 50; Models, Molecular; Quantitative Structure-Activity Relationship; Rats | 2002 |
3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates.
Topics: Animals; Crystallography, X-Ray; Dimethylallyltranstransferase; Diphosphonates; Imidazoles; Leishmania major; Models, Molecular; Picolinic Acids; Pyridines; Quantitative Structure-Activity Relationship; Zoledronic Acid | 2003 |
Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
Topics: Animals; Antimalarials; Antiprotozoal Agents; Cell Line; Cricetinae; Diphosphonates; Entamoeba histolytica; Entamoebiasis; Humans; In Vitro Techniques; Liver Abscess; Malaria; Mice; Mice, Inbred BALB C; Plasmodium berghei; Plasmodium falciparum; Structure-Activity Relationship | 2004 |
Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
Topics: Alkyl and Aryl Transferases; Animals; Cell Division; Cell Line; Diphosphonates; Geranyltranstransferase; Humans; Leishmania major; Lymphocyte Activation; Models, Molecular; Quantitative Structure-Activity Relationship; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2004 |
Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Bone Resorption; Calcium; Dictyostelium; Diphosphonates; Geranyltranstransferase; Humans; In Vitro Techniques; Leishmania major; Metatarsal Bones; Mice; Models, Molecular; Pyridinium Compounds; Quantitative Structure-Activity Relationship; Receptors, Antigen, T-Cell, gamma-delta; Trypanocidal Agents | 2005 |
Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
Topics: Aldose-Ketose Isomerases; Alkyl and Aryl Transferases; Animals; Antiprotozoal Agents; Cell Line; Diphosphonates; Fosfomycin; Geranyltranstransferase; Humans; Mice; Models, Molecular; Multienzyme Complexes; Oxidoreductases; Quantitative Structure-Activity Relationship; Toxoplasma; Toxoplasmosis | 2005 |
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
Topics: Binding Sites; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Models, Molecular; Molecular Structure; Nitrogen; Stereoisomerism; Structure-Activity Relationship; Time Factors | 2008 |
Determination of the microscopic equilibrium dissociation constants for risedronate and its analogues reveals two distinct roles for the nitrogen atom in nitrogen-containing bisphosphonate drugs.
Topics: Animals; Bone Density Conservation Agents; Dictyostelium; Diphosphonates; Etidronic Acid; Hydrogen-Ion Concentration; Microscopy; Nitrogen; Proteome; Risedronic Acid; Spectrometry, Mass, Electrospray Ionization; Spectrometry, Mass, Fast Atom Bombardment | 2008 |
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation.
Topics: Antineoplastic Agents; Crystallography, X-Ray; Diphosphonates; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Farnesyltranstransferase; Humans; K562 Cells; Magnetic Resonance Spectroscopy; Models, Molecular; Quantitative Structure-Activity Relationship | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Remarkable potential of the α-aminophosphonate/phosphinate structural motif in medicinal chemistry.
Topics: Amino Acid Motifs; Chemistry, Pharmaceutical; Humans; Organophosphonates; Phosphinic Acids | 2011 |
Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis.
Topics: Animals; Calcification, Physiologic; Cell Line; Diphosphonates; Enzyme Inhibitors; Geranylgeranyl-Diphosphate Geranylgeranyltransferase; Geranyltranstransferase; Humans; Mice; Molecular Docking Simulation; Osteoclasts; Osteogenesis; RAW 264.7 Cells | 2018 |
A guanidinium-based inhibitor of a type I isopentenyl diphosphate isomerase.
Topics: Carbon-Carbon Double Bond Isomerases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Escherichia coli; Geranyltranstransferase; Guanidine; Hemiterpenes; Humans; Molecular Structure; Structure-Activity Relationship | 2020 |
Synthesis and biological evaluation of indolylglyoxylamide bisphosphonates, antimitotic microtubule-targeting derivatives of indibulin with improved aqueous solubility.
Topics: Acetamides; Animals; Antimitotic Agents; Cell Line, Tumor; Diphosphonates; Drug Screening Assays, Antitumor; Embryo, Nonmammalian; Humans; Indoles; Sea Urchins; Solubility | 2020 |
Diflunisal Derivatives as Modulators of ACMS Decarboxylase Targeting the Tryptophan-Kynurenine Pathway.
Topics: Bacterial Proteins; Binding Sites; Biosynthetic Pathways; Carboxy-Lyases; Catalytic Domain; Crystallography, X-Ray; Diflunisal; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kynurenine; Molecular Docking Simulation; NAD; Pseudomonas fluorescens; Structure-Activity Relationship; Tryptophan | 2021 |
BM 21.0955, a potent new bisphosphonate to inhibit bone resorption.
Topics: Alendronate; Animals; Benzoates; Bone Resorption; Calcium; Clodronic Acid; Diphosphonates; Etidronic Acid; Ibandronic Acid; Injections, Intravenous; Osteoclasts; Pamidronate; Rats; Retinoids; Risedronic Acid; Spectrophotometry, Atomic; Tetracycline; Thyroxine | 1991 |
Nonclinical model for assessing gastric effects of bisphosphonates.
Topics: Alendronate; Animals; Chelating Agents; Diphosphonates; Edetic Acid; Egtazic Acid; Etidronic Acid; Indomethacin; Male; Pamidronate; Rats; Rats, Sprague-Dawley; Risedronic Acid; Stomach | 1997 |
Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
Topics: Alendronate; Animals; Apoptosis; Bone Resorption; Cells, Cultured; Clodronic Acid; Diphosphonates; Enzyme Inhibitors; Etidronic Acid; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Ibandronic Acid; Lovastatin; Macrophages; Mevalonic Acid; Mice; Osteoclasts; Protein Prenylation; Protein Processing, Post-Translational; ras Proteins; Risedronic Acid; Structure-Activity Relationship | 1998 |
Comparative study of potential for bisphosphonates to damage gastric mucosa of rats.
Topics: Alendronate; Animals; Calcium Channel Blockers; Dose-Response Relationship, Drug; Etidronic Acid; Female; Gastric Mucosa; Rats; Rats, Sprague-Dawley; Risedronic Acid | 1998 |
Esophageal irritation due to alendronate sodium tablets: possible mechanisms.
Topics: Alendronate; Animals; Bone Resorption; Diphosphonates; Dogs; Esophagus; Etidronic Acid; Mucous Membrane; Risedronic Acid | 1998 |
Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships.
Topics: Alendronate; Animals; Bone and Bones; Bone Resorption; Calcification, Physiologic; Calcium; Culture Techniques; Etidronic Acid; Female; Mice; Pregnancy; Risedronic Acid; Structure-Activity Relationship | 1998 |
Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase.
Topics: Alendronate; Animals; Apoptosis; Calcium Channel Blockers; Caspase Inhibitors; Caspases; Clodronic Acid; Diphosphonates; Diterpenes; Enzyme Activation; Etidronic Acid; Macrophage Colony-Stimulating Factor; Male; MAP Kinase Kinase Kinases; Mevalonic Acid; Mice; Mice, Inbred BALB C; Osteoclasts; Protein Prenylation; Protein Serine-Threonine Kinases; Risedronic Acid; Signal Transduction; Staurosporine; Time Factors | 1999 |
Iatrogenic osteoporosis.
Topics: Alendronate; Calcium Channel Blockers; Etidronic Acid; Female; Glucocorticoids; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid | 1999 |
Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.
Topics: Alendronate; Animals; Bone Remodeling; Calcium Channel Blockers; Dogs; Etidronic Acid; Female; Radiography; Ribs; Risedronic Acid | 2000 |
The intracellular target for the antiresorptive aminobisphosphonate drugs in Dictyostelium discoideum is the enzyme farnesyl diphosphate synthase.
Topics: Alendronate; Alkyl and Aryl Transferases; Amino Acid Sequence; Animals; Base Sequence; Bone Resorption; Dictyostelium; Diphosphonates; DNA Primers; Etidronic Acid; Farnesyl-Diphosphate Farnesyltransferase; Geranyltranstransferase; Molecular Sequence Data; Risedronic Acid; RNA, Messenger; Sequence Homology, Amino Acid | 2000 |
New developments in osteoporosis treatment.
Topics: Alendronate; Anticholesteremic Agents; Drug Administration Schedule; Etidronic Acid; Humans; Osteoporosis; Parathyroid Hormone; Risedronic Acid | 2000 |
Gastric damage in the rat with nitrogen-containing bisphosphonates depends on pH.
Topics: Administration, Oral; Alendronate; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; Diphosphonates; Etidronic Acid; Hydrogen-Ion Concentration; Indomethacin; Male; Pamidronate; Rats; Rats, Sprague-Dawley; Risedronic Acid; Stomach; Structure-Activity Relationship | 2000 |
Drugs for prevention and treatment of postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Resorption; Breast Neoplasms; Calcitonin; Calcium; Calcium Channel Blockers; Clinical Trials as Topic; Densitometry; Dose-Response Relationship, Drug; Estrogens; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Vitamin D | 2000 |
Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Diphosphonates; Etidronic Acid; Gastric Mucosa; Indomethacin; Male; Pamidronate; Phosphatidylcholines; Rats; Rats, Sprague-Dawley; Risedronic Acid; Surface Properties | 2000 |
Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats.
Topics: Alendronate; Animals; Body Weight; Etidronic Acid; Female; Femur; Hindlimb Suspension; Osteoporosis; Rats; Rats, Sprague-Dawley; Risedronic Acid | 2000 |
In vivo effects of bisphosphonates on the osteoclast mevalonate pathway.
Topics: Alendronate; Alkyl and Aryl Transferases; Animals; Bone Resorption; Diphosphonates; Enzyme Inhibitors; Etidronic Acid; Geranyltranstransferase; Hydroxymethylglutaryl CoA Reductases; Ibandronic Acid; Male; Mevalonic Acid; Osteoclasts; Rats; Rats, Sprague-Dawley; Risedronic Acid | 2000 |
Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: does site-specificity exist?
Topics: Aged; Alendronate; Calcitriol; Calcium Channel Agonists; Calcium Channel Blockers; Estrogen Antagonists; Etidronic Acid; Female; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Spinal Fractures | 2000 |
Once-a-week alendronate (Fosamax).
Topics: Alendronate; Bone Resorption; Calcium Channel Blockers; Chemistry, Pharmaceutical; Clinical Trials as Topic; Dose-Response Relationship, Drug; Etidronic Acid; Humans; Osteoporosis, Postmenopausal; Risedronic Acid | 2001 |
Absolute vs. relative numbers in evaluating drug therapy.
Topics: Alendronate; Data Interpretation, Statistical; Etidronic Acid; Female; Fractures, Bone; Humans; Informed Consent; Osteoporosis, Postmenopausal; Patient Education as Topic; Patient Selection; Risedronic Acid; Risk Assessment; Risk Factors | 2001 |
Re: Lanza et al.--Endoscopic comparison of alendronate and risedronate.
Topics: Alendronate; Etidronic Acid; Gastroscopy; Humans; Risedronic Acid; Stomach Ulcer | 2001 |
Osteoporosis in men.
Topics: Alendronate; Calcium Channel Blockers; Etidronic Acid; Humans; Male; Osteoporosis; Risedronic Acid | 2001 |
Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates.
Topics: Alendronate; Antigens; Cell Line, Transformed; Cytotoxicity, Immunologic; Diphosphonates; Etidronic Acid; Gene Rearrangement, delta-Chain T-Cell Antigen Receptor; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Humans; Interferon-gamma; Interleukin-2; Jurkat Cells; Lymphocyte Activation; Monocytes; Multiple Myeloma; Neoplasms; Neoplastic Stem Cells; Osteoclasts; Osteoporosis; Pamidronate; Receptors, Antigen, T-Cell, gamma-delta; Recombinant Fusion Proteins; Risedronic Acid; Structure-Activity Relationship; T-Lymphocyte Subsets; Transfection | 2001 |
Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis.
Topics: Actins; Alendronate; Animals; Apoptosis; Bone Resorption; Cytoskeleton; Etidronic Acid; Mice; Osteoclasts; Risedronic Acid | 2001 |
Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage.
Topics: Alendronate; Animals; Bone Density; Bone Regeneration; Diphosphonates; Dogs; Etidronic Acid; Female; Fractures, Bone; Rib Fractures; Risedronic Acid; Stochastic Processes | 2001 |
[Economic aspects of osteoporosis therapy. What does a prevented fracture cost?].
Topics: Aged; Alendronate; Cost-Benefit Analysis; Etidronic Acid; Female; Fractures, Spontaneous; Germany; Humans; National Health Programs; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Spinal Fractures | 2001 |
Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date.
Topics: Aged; Alendronate; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, Bone; Hip Fractures; Humans; Osteoporosis, Postmenopausal; Risedronic Acid; Spinal Fractures; Treatment Outcome | 2002 |
[Patients with fractures are in the front line for osteoporosis treatment but how to treat?].
Topics: Alendronate; Bone Density; Calcitonin; Etidronic Acid; Fractures, Bone; Health Services Accessibility; Humans; Osteoporosis; Physician's Role; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors | 2001 |
[Osteoporosis therapy. A comparison of bisphosphonates].
Topics: Aged; Alendronate; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risedronic Acid; Treatment Outcome | 2002 |
Bisphosphonates and the upper gastrointestinal tract: skeletal gain without visceral pain?
Topics: Alendronate; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Osteoporosis, Postmenopausal; Risedronic Acid | 2002 |
Effects of risedronate, alendronate, and etidronate on the viability and activity of rat bone marrow stromal cells in vitro.
Topics: Alendronate; Animals; Bone and Bones; Bone Marrow Cells; Cell Survival; Diphosphonates; Diterpenes; Etidronic Acid; Farnesol; Fibroblasts; Models, Animal; Rats; Rats, Wistar; Risedronic Acid; Stromal Cells | 2003 |
[Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate].
Topics: Activities of Daily Living; Age Factors; Alendronate; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Disabled Persons; Etidronic Acid; Female; Femoral Fractures; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Pain; Raloxifene Hydrochloride; Risedronic Acid; Sex Factors; Spinal Fractures | 2002 |
Medications for postmenopausal osteoporosis prevention.
Topics: Alendronate; Bone Density; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators | 2002 |
[Evidence-based therapy of osteoporosis--comment on DMW 17/2003].
Topics: Alendronate; Budgets; Drug Costs; Etidronic Acid; Evidence-Based Medicine; Germany; Humans; National Health Programs; Osteoporosis; Risedronic Acid | 2003 |
Canine cancellous bone microarchitecture after one year of high-dose bisphosphonates.
Topics: Alendronate; Animals; Bone Development; Compressive Strength; Dogs; Etidronic Acid; Female; Growth Plate; Imaging, Three-Dimensional; Lumbar Vertebrae; Radiography; Risedronic Acid; Stress, Mechanical; Treatment Outcome | 2003 |
Spectrophotometric determination of some drugs for osteoporosis.
Topics: Alendronate; Etidronic Acid; Osteoporosis; Risedronic Acid; Spectrophotometry | 2003 |
Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs.
Topics: Alendronate; Animals; Bone Density; Bone Remodeling; Calcification, Physiologic; Carbonates; Collagen; Crystallography; Diphosphonates; Dogs; Etidronic Acid; Female; Microscopy, Electron, Scanning; Osteogenesis; Osteoporosis; Phosphates; Proteins; Ribs; Risedronic Acid; Scattering, Radiation; Spectrophotometry, Infrared; Thoracic Vertebrae; Tomography, X-Ray Computed; X-Ray Diffraction | 2003 |
Osteoblast proliferation and maturation by bisphosphonates.
Topics: Adaptation, Physiological; Alendronate; Cell Differentiation; Cell Division; Cell Line; Cell Survival; Cells, Cultured; Diphosphonates; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Etidronic Acid; Extracellular Matrix Proteins; Humans; Osteoblasts; Risedronic Acid | 2004 |
Mucosal irritative and healing impairment action of risedronate in rat stomachs: comparison with alendronate.
Topics: Acetic Acid; Alendronate; Animals; Diphosphonates; Etidronic Acid; Gastric Mucosa; Male; Rats; Rats, Sprague-Dawley; Risedronic Acid; Stomach Ulcer; Wound Healing | 2004 |
[Bisphosphonates in the prevention of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis].
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid | 2003 |
Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Matrix; Calcification, Physiologic; Dogs; Etidronic Acid; Female; Risedronic Acid | 2004 |
[Osteoporosis therapy. Bisphosphonates compared].
Topics: Alendronate; Bone Density; Clinical Trials as Topic; Diphosphonates; Double-Blind Method; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Risedronic Acid; Time Factors | 2003 |
[Data comparison of osteoporosis patients demonstrates nasal administration is not optimal].
Topics: Administration, Intranasal; Administration, Oral; Aerosols; Aged; Alendronate; Calcitonin; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Male; Middle Aged; Osteoporosis; Risedronic Acid; Treatment Outcome | 2004 |
New treatments for brittle bones.
Topics: Alendronate; Animals; Bone Density; Etidronic Acid; Humans; Osteoporosis; Risedronic Acid | 2004 |
Coming to grips with bone loss.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Remodeling; Carrier Proteins; Estrenes; Estrogens; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Membrane Glycoproteins; Osteoblasts; Osteoclasts; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Parathyroid Hormone-Related Protein; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Estrogen; Risedronic Acid; Signal Transduction; Teriparatide; Vitamin D | 2004 |
[Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?].
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Etidronic Acid; Evidence-Based Medicine; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures | 2004 |
[Weekly Fosamax tablet is significantly more effective than risedronate daily, as results of the Head-to-Head Study show].
Topics: Alendronate; Bone Density; Drug Administration Schedule; Etidronic Acid; Female; Humans; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risedronic Acid; Treatment Outcome | 2004 |
[Are there differences in bisphosphonates? (interview by Dr. Beate Schumacher)].
Topics: Alendronate; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Fractures, Spontaneous; Humans; Meta-Analysis as Topic; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Treatment Outcome | 2004 |
Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Cohort Studies; Cost-Benefit Analysis; Etidronic Acid; Female; Germany; Hip Fractures; Humans; Incidence; Insurance, Pharmaceutical Services; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid | 2004 |
Pharmaceutical care and community pharmacists' understanding of bisphosphonate dosing information.
Topics: Alendronate; Community Pharmacy Services; Diphosphonates; Drug Administration Schedule; Drug Information Services; Education, Pharmacy, Continuing; Etidronic Acid; Female; Humans; Knowledge; Male; Pharmacists; Risedronic Acid; Surveys and Questionnaires | 2004 |
[Update 2004. Osteoporosis--management--current status].
Topics: Aged; Aged, 80 and over; Alendronate; Calcium, Dietary; Cross-Sectional Studies; Etidronic Acid; Female; Fractures, Spontaneous; Germany; Health Surveys; Hip Fractures; Humans; Male; Middle Aged; Osteoporosis; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risedronic Acid; Spinal Fractures; Vitamin D | 2004 |
[Routine osteoporosis therapy].
Topics: Administration, Intranasal; Aged; Alendronate; Calcitonin; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Fractures, Spontaneous; Germany; Humans; Male; Middle Aged; Osteoporosis; Risedronic Acid; Risk; United States | 2004 |
Bisphosphonates induce inflammation and rupture of atherosclerotic plaques in apolipoprotein-E null mice.
Topics: Alendronate; Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Carotid Stenosis; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Etidronic Acid; Female; Mice; Mice, Inbred C57BL; Mice, Knockout; Risedronic Acid; Treatment Outcome | 2005 |
[FACT study: benefits of alendronate].
Topics: Aged; Alendronate; Bone Density; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Female; Humans; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Placebos; Randomized Controlled Trials as Topic; Risedronic Acid; Time Factors | 2005 |
Alendronate and risedronate: reports of severe bone, joint, and muscle pain.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alendronate; Arthralgia; Bone and Bones; Child; Etidronic Acid; Female; Humans; Male; Middle Aged; Pain; Risedronic Acid | 2005 |
Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis.
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2005 |
Bisphosphonates stimulate an endogenous nonselective cation channel in Xenopus oocytes: potential mechanism of action.
Topics: Alendronate; Animals; Diphosphonates; Electric Impedance; Etidronic Acid; Ion Channels; Membrane Potentials; Oocytes; Rats; Risedronic Acid; Xenopus | 2005 |
Alendronate (Fosamax) and risedronate (Actonel) revisited.
Topics: Alendronate; Bone Density; Bone Remodeling; Dose-Response Relationship, Drug; Etidronic Acid; Female; Humans; Maxillary Diseases; Middle Aged; Osteonecrosis; Osteoporosis, Postmenopausal; Risedronic Acid | 2005 |
[Calcium gaps in osteoporosis patients close. Blister pack simplifies comedication of calcium and bisphosphonates].
Topics: Alendronate; Calcitonin; Calcium; Clinical Trials as Topic; Cohort Studies; Drug Packaging; Etidronic Acid; Female; Follow-Up Studies; Fractures, Bone; Humans; Longitudinal Studies; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Time Factors | 2005 |
[Marketing--alendronate versus risedronate].
Topics: Alendronate; Bone Density; Drug Information Services; Etidronic Acid; Humans; Marketing; Osteoporosis, Postmenopausal; Risedronic Acid | 2005 |
[To increase bone density faster and stronger].
Topics: Alendronate; Bone Density; Bone Resorption; Etidronic Acid; Female; Humans; Middle Aged; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Placebos; Randomized Controlled Trials as Topic; Risedronic Acid; Tablets; Time Factors | 2005 |
Alendronate (Fosamax) and risedronate (Actonel) revisited.
Topics: Alendronate; Etidronic Acid; Humans; Osteoporosis; Risedronic Acid | 2005 |
Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
Topics: Age Factors; Aged; Alendronate; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Insurance Claim Review; Insurance, Pharmaceutical Services; Managed Care Programs; Middle Aged; Osteoporosis, Postmenopausal; Outcome Assessment, Health Care; Patient Compliance; Proportional Hazards Models; Risedronic Acid; Self Administration; United States | 2005 |
Bone remodeling at the iliac crest can predict the changes in remodeling dynamics, microdamage accumulation, and mechanical properties in the lumbar vertebrae of dogs.
Topics: Administration, Oral; Alendronate; Animals; Biomechanical Phenomena; Bone Remodeling; Calcium Channel Blockers; Dogs; Etidronic Acid; Female; Ilium; Lumbar Vertebrae; Risedronic Acid | 2005 |
[Antiresorptive treatment after proximal femur fracture].
Topics: Alendronate; Bone Density Conservation Agents; Calcium; Drug Therapy, Combination; Etidronic Acid; Hip Fractures; Humans; Retrospective Studies; Risedronic Acid; Vitamin D | 2005 |
Structure and mechanism of the farnesyl diphosphate synthase from Trypanosoma cruzi: implications for drug design.
Topics: Alendronate; Amino Acid Sequence; Animals; Drug Design; Etidronic Acid; Geranyltranstransferase; Magnesium; Models, Molecular; Molecular Sequence Data; Protein Structure, Secondary; Protozoan Proteins; Risedronic Acid; Sequence Alignment; Sequence Homology, Amino Acid; Trypanocidal Agents; Trypanosoma cruzi | 2006 |
[Examination and treatment of orthopedic-surgery patients with osteoporosis-related fragility fractures].
Topics: Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Etidronic Acid; Female; Fracture Healing; Fractures, Spontaneous; Hip Fractures; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Patient Care Planning; Patient Education as Topic; Risedronic Acid; Vitamin D | 2005 |
Paget's disease and bisphosphonates.
Topics: Administration, Oral; Alendronate; Cost-Benefit Analysis; Diphosphonates; Drug Administration Schedule; Drug Costs; Etidronic Acid; Humans; Imidazoles; Osteitis Deformans; Risedronic Acid; Zoledronic Acid | 2005 |
Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users.
Topics: Alendronate; Databases as Topic; Diphosphonates; Drug Prescriptions; Drug Utilization; Etidronic Acid; Female; Glucocorticoids; Health Care Surveys; Humans; Male; Middle Aged; Osteoporosis; Patient Compliance; Pharmacies; Process Assessment, Health Care; Quality of Health Care; Risedronic Acid; Self Disclosure; Time Factors | 2006 |
Osteoporosis management in a Medicaid population after the Women's Health Initiative study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Diphosphonates; Drug Utilization; Estrogen Receptor Modulators; Estrogens; Etidronic Acid; Female; Humans; Medicaid; Middle Aged; Osteoporosis, Postmenopausal; Outcome Assessment, Health Care; Pennsylvania; Practice Patterns, Physicians'; Risedronic Acid; Women's Health Services | 2006 |
Chemical makeup of microdamaged bone differs from undamaged bone.
Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Carbonates; Collagen; Dogs; Etidronic Acid; Lumbar Vertebrae; Phosphates; Proteins; Random Allocation; Risedronic Acid; Spectrophotometry, Infrared; Synchrotrons; Time Factors | 2006 |
Is the increase in osteoporosis prevention a result of the audit?
Topics: Adrenal Cortex Hormones; Alendronate; Bone Density Conservation Agents; Calcium; Clinical Trials as Topic; Etidronic Acid; Humans; Medical Audit; Neurology; Osteoporosis; Practice Guidelines as Topic; Risedronic Acid; United Kingdom; Vitamin D | 2006 |
Differential effects of bisphosphonates on breast cancer cell lines.
Topics: Alendronate; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Cyclin D1; Diphosphonates; DNA Fragmentation; Etidronic Acid; Female; Flow Cytometry; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Risedronic Acid; RNA, Messenger; Zoledronic Acid | 2007 |
Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Topics: Age Factors; Aged; Alendronate; Bone Density Conservation Agents; Databases, Factual; Drug Administration Schedule; Drug Prescriptions; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Middle Aged; Multivariate Analysis; Netherlands; Osteoporosis, Postmenopausal; Patient Compliance; Risedronic Acid | 2006 |
Bisphosphonates activate nucleotide receptors signaling and induce the expression of Hsp90 in osteoblast-like cell lines.
Topics: Adenosine Triphosphate; Alendronate; Apyrase; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Survival; Diphosphonates; Etidronic Acid; HSP90 Heat-Shock Proteins; Humans; Mass Spectrometry; Mitogen-Activated Protein Kinase Kinases; Models, Biological; Osteoblasts; Receptors, Purinergic P2; Risedronic Acid; Signal Transduction; Suramin | 2006 |
Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Female; Glucocorticoids; Humans; Logistic Models; Male; Middle Aged; Osteoporosis; Patient Compliance; Proportional Hazards Models; Risedronic Acid | 2006 |
Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Calcification, Physiologic; Diphosphonates; Dogs; Dose-Response Relationship, Drug; Etidronic Acid; Female; Lumbar Vertebrae; Risedronic Acid; Time Factors | 2006 |
Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Comorbidity; Etidronic Acid; Female; Humans; Male; Managed Care Programs; Middle Aged; Osteoporosis; Patient Compliance; Raloxifene Hydrochloride; Risedronic Acid | 2006 |
Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Femur; Injections, Subcutaneous; Osteoblasts; Rats; Rats, Sprague-Dawley; Risedronic Acid; Stress, Mechanical; Tibia | 2006 |
Cost-effectiveness of alternative treatments for women with osteoporosis in Canada.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Canada; Cost-Benefit Analysis; Decision Support Techniques; Etidronic Acid; Female; Humans; Markov Chains; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid | 2006 |
[Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly].
Topics: Aged; Aged, 80 and over; Alendronate; Biological Availability; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Etidronic Acid; Female; Geranyltranstransferase; Humans; Imidazoles; Male; Multicenter Studies as Topic; Osteitis Deformans; Osteoporosis, Postmenopausal; Patient Compliance; Placebos; Randomized Controlled Trials as Topic; Risedronic Acid; Surveys and Questionnaires; Time Factors; Zoledronic Acid | 2006 |
Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Italy; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Risk Factors; Vitamin D | 2006 |
Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
Topics: Aged; Aged, 80 and over; Alendronate; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Florida; Glucocorticoids; Hospitals, Veterans; Humans; Male; Middle Aged; Osteoporosis; Prevalence; Retrospective Studies; Risedronic Acid; Sex Factors | 2006 |
Antiremodeling agents influence osteoblast activity differently in modeling and remodeling sites of canine rib.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Matrix; Bone Remodeling; Dogs; Etidronic Acid; Female; Osteoblasts; Periosteum; Raloxifene Hydrochloride; Ribs; Risedronic Acid | 2006 |
A general approach for the quantitative analysis of bisphosphonates in human serum and urine by high-performance liquid chromatography/tandem mass spectrometry.
Topics: Alendronate; Bone Density Conservation Agents; Chromatography, High Pressure Liquid; Diazomethane; Etidronic Acid; Humans; Risedronic Acid; Sensitivity and Specificity; Tandem Mass Spectrometry | 2006 |
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Evaluation; Etidronic Acid; Female; Fractures, Bone; Hip Fractures; Humans; Incidence; Osteoporosis, Postmenopausal; Retrospective Studies; Risedronic Acid; Treatment Outcome; United States | 2007 |
Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading.
Topics: Alendronate; Animals; Apoptosis; Biomechanical Phenomena; Bone Density Conservation Agents; Etidronic Acid; Female; Osteocytes; Rats; Rats, Sprague-Dawley; Risedronic Acid; Stress, Mechanical; Ulna | 2007 |
European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; Europe; Female; Humans; Interviews as Topic; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Patient Satisfaction; Risedronic Acid | 2006 |
Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance.
Topics: Aged; Aged, 80 and over; Alendronate; Attitude to Health; Bone Density; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Cross-Over Studies; Drug Administration Schedule; Etidronic Acid; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Patient Compliance; Proportional Hazards Models; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Risk Assessment; Severity of Illness Index; Treatment Outcome; United States | 2007 |
Bisphosphonates. A cornerstone of osteoporosis treatment.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Female; Humans; Ibandronic Acid; Mandibular Diseases; Osteonecrosis; Osteoporosis; Risedronic Acid | 2007 |
[Correlation between studies and general practice].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Etidronic Acid; Family Practice; Female; Fractures, Spontaneous; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risedronic Acid; Treatment Outcome | 2006 |
Oral bisphosphonate associated osteonecrosis of the jaws: three case reports.
Topics: Administration, Oral; Aged; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chlorhexidine; Clindamycin; Diphosphonates; Etidronic Acid; Facial Pain; Female; Humans; Ibandronic Acid; Jaw Diseases; Middle Aged; Oral Fistula; Osteonecrosis; Penicillin V; Risedronic Acid; Tooth Extraction | 2007 |
[Osteoporosis compounds in general practice. That is REAL: in routine practice the better choice].
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Etidronic Acid; Female; Fractures, Spontaneous; Hip Fractures; Humans; Osteoporosis, Postmenopausal; Retrospective Studies; Risedronic Acid; Spinal Fractures | 2007 |
Yearly zoledronic acid in postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2007 |
Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate.
Topics: Aged; Aged, 80 and over; Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Logistic Models; Male; Osteoporosis; Patient Compliance; Quality of Life; Risedronic Acid; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2007 |
Changes in vertebral strength-density and energy absorption-density relationships following bisphosphonate treatment in beagle dogs.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Compressive Strength; Diphosphonates; Dogs; Etidronic Acid; Female; Lumbar Vertebrae; Models, Animal; Risedronic Acid | 2008 |
Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow-up, and the incidence of complications in two private practices.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Dental Care for Chronically Ill; Dental Implantation, Endosseous; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Jaw Diseases; Middle Aged; Osseointegration; Osteonecrosis; Retrospective Studies; Risedronic Acid; Tooth Extraction; Wound Healing | 2007 |
Hip fractures in users of first- vs. second-generation bisphosphonates.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Diphosphonates; Etidronic Acid; Female; Hip Fractures; Hospitalization; Humans; Ontario; Osteoporosis, Postmenopausal; Retrospective Studies; Risedronic Acid; Social Class | 2007 |
Osteoporosis: non-hormonal treatment.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcitonin; Calcium, Dietary; Denosumab; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Thiophenes; Vitamin D; Women's Health | 2007 |
Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women.
Topics: Alendronate; Drug Administration Schedule; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Patient Compliance; Postmenopause; Prospective Studies; Raloxifene Hydrochloride; Risedronic Acid | 2007 |
[Osteoporosis treatment: choices and options].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Etidronic Acid; Humans; Osteoporosis; Risedronic Acid; Treatment Outcome | 2007 |
Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Canada; Cost-Benefit Analysis; Etidronic Acid; Female; Hip Fractures; Humans; Models, Biological; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Risedronic Acid; Severity of Illness Index | 2008 |
Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.
Topics: Alendronate; Biomarkers; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Etidronic Acid; Female; Humans; Jaw Diseases; Middle Aged; Osteonecrosis; Peptides; Prospective Studies; Risedronic Acid; Time Factors | 2007 |
Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra.
Topics: Alendronate; Amino Acids; Animals; Arginine; Bone Density Conservation Agents; Bone Remodeling; Collagen; Diphosphonates; Dogs; Dose-Response Relationship, Drug; Etidronic Acid; Female; Lumbar Vertebrae; Lysine; Raloxifene Hydrochloride; Risedronic Acid | 2008 |
NMR investigations of the static and dynamic structures of bisphosphonates on human bone: a molecular model.
Topics: Alendronate; Biochemistry; Bone and Bones; Bone Density Conservation Agents; Crystallography, X-Ray; Diphosphonates; Etidronic Acid; Humans; Hydrogen; Imidazoles; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Pamidronate; Protein Structure, Tertiary; Risedronic Acid; Zoledronic Acid | 2008 |
Osteoporosis treatment and fracture incidence: the ICARO longitudinal study.
Topics: Adult; Age Factors; Aged; Alendronate; Body Mass Index; Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Humans; Italy; Longitudinal Studies; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Treatment Failure | 2008 |
Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Cell Line, Tumor; Cell Survival; Coculture Techniques; Dentin; Diphosphonates; Endocytosis; Etidronic Acid; Extracellular Matrix Proteins; Macrophages; Mice; Microscopy, Fluorescence; Osteoblasts; Osteoclasts; Protein Prenylation; Rabbits; rap1 GTP-Binding Proteins; Risedronic Acid; Skull | 2008 |
In vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70 mg) and in vivo implications.
Topics: Alendronate; Biological Availability; Bone Density Conservation Agents; Canada; Diphosphonates; Drugs, Generic; Etidronic Acid; Germany; Humans; In Vitro Techniques; Netherlands; Risedronic Acid; Tablets; Technology, Pharmaceutical; Time Factors; United Kingdom | 2008 |
Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis.
Topics: Aged; Alendronate; Analysis of Variance; Bone Density; Cohort Studies; Databases, Factual; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Female; Humans; Logistic Models; Middle Aged; Netherlands; Osteoporosis, Postmenopausal; Patient Compliance; Probability; Prognosis; Retrospective Studies; Risedronic Acid; Risk Factors; Severity of Illness Index; Treatment Outcome; Treatment Refusal | 2008 |
Osteonecrosis of the jaw: new developments in an old disease.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Humans; Jaw Diseases; Osteonecrosis; Risedronic Acid; Risk Factors | 2008 |
Summaries for patients. Drug therapy for osteoporosis.
Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Male; New Jersey; Osteoporosis; Osteoporosis, Postmenopausal; Pennsylvania; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors | 2008 |
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Male; New Jersey; Osteoporosis; Osteoporosis, Postmenopausal; Pennsylvania; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors | 2008 |
Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Epidemiologic Methods; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis; Risedronic Acid; Risk Factors; Treatment Refusal | 2008 |
Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Cohort Studies; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Male; Middle Aged; Osteoporosis; Retrospective Studies; Risedronic Acid; Treatment Outcome; Vitamin D; Vitamin D Deficiency | 2008 |
Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats.
Topics: Alendronate; Animals; Body Weight; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Etidronic Acid; Female; Ovariectomy; Rats; Rats, Sprague-Dawley; Risedronic Acid | 2008 |
Vitamin D status and response to treatment in post-menopausal osteoporosis.
Topics: Activities of Daily Living; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcium; Confounding Factors, Epidemiologic; Dietary Supplements; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Logistic Models; Middle Aged; Odds Ratio; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Risk; Treatment Outcome; Vitamin D; Vitamin D Deficiency | 2009 |
Identification of material parameters based on Mohr-Coulomb failure criterion for bisphosphonate treated canine vertebral cancellous bone.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density Conservation Agents; Computer Simulation; Diphosphonates; Dogs; Etidronic Acid; Hardness Tests; Nanotechnology; Risedronic Acid; Shear Strength; Stress, Mechanical | 2008 |
Maximizing effectiveness of bisphosphonate therapy for osteoporosis.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Imidazoles; Medication Adherence; Osteoporosis; Physician-Patient Relations; Risedronic Acid; Risk Factors; Zoledronic Acid | 2008 |
Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Budgets; Cost-Benefit Analysis; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Health Care Costs; Humans; Ibandronic Acid; Markov Chains; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Risedronic Acid; Risk Assessment; Risk Factors; United States | 2008 |
DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Diphosphonates; Etidronic Acid; Female; Femur; Fractures, Bone; Hip; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Assessment | 2009 |
Osteoporotic fracture management in India: a survey of orthopaedic surgeons.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Etidronic Acid; Fractures, Bone; Health Care Surveys; Humans; India; Orthopedics; Osteoporosis; Risedronic Acid | 2008 |
The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Hip Fractures; Humans; Male; Middle Aged; Patient Compliance; Risedronic Acid | 2009 |
Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Risedronic Acid | 2008 |
Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Bone Matrix; Diphosphonates; Dogs; Dose-Response Relationship, Drug; Etidronic Acid; Female; Glycation End Products, Advanced; Models, Animal; Osteoporosis; Risedronic Acid | 2009 |
RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Hip Fractures; Humans; Incidence; Medication Adherence; Osteoporosis; Postmenopause; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Reduction Behavior; Spinal Fractures; Treatment Outcome | 2009 |
[Treatment of osteoporosis in the elderly: what is the evidence?].
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Alendronate; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Teriparatide; Treatment Outcome | 2008 |
Differences in persistence among different weekly oral bisphosphonate medications.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drugs, Generic; Epidemiologic Methods; Etidronic Acid; Female; Fractures, Bone; Humans; Length of Stay; Male; Medication Adherence; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Patient Acceptance of Health Care; Quebec; Risedronic Acid; Sex Factors | 2009 |
Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Confidence Intervals; Etidronic Acid; Female; Fractures, Bone; Health Care Costs; Humans; Male; Osteoporosis; Risedronic Acid; Risk Factors | 2009 |
[New bisphosphonates and trends in drug therapy for osteoporosis: preface].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Humans; Imidazoles; Osteoporosis; Risedronic Acid; Zoledronic Acid | 2009 |
Medical treatment of otosclerosis: rationale for use of bisphosphonates.
Topics: Aged; Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Cell Death; Combined Modality Therapy; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ear, Inner; Ear, Middle; Etidronic Acid; Follow-Up Studies; Hearing Aids; Hearing Loss, Sensorineural; Humans; Male; Middle Aged; Osteoclasts; Osteoprotegerin; Otosclerosis; Risedronic Acid; Speech Discrimination Tests; Speech Reception Threshold Test; Stapes Surgery; Tinnitus | 2008 |
Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Atrial Fibrillation; Atrial Flutter; Bone Density Conservation Agents; Case-Control Studies; Databases, Factual; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Etidronic Acid; Female; Humans; Incidence; Middle Aged; Risedronic Acid; Risk; Time Factors | 2009 |
Comparative gastrointestinal safety of weekly oral bisphosphonates.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Epidemiologic Methods; Etidronic Acid; Female; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Hospitalization; Humans; Male; Osteoporosis; Pennsylvania; Risedronic Acid; Treatment Outcome | 2009 |
Theoretical analysis of alendronate and risedronate effects on canine vertebral remodeling and microdamage.
Topics: Alendronate; Animals; Computer Simulation; Disease Models, Animal; Dogs; Etidronic Acid; Fractures, Bone; Risedronic Acid; Spine; Substrate Specificity | 2009 |
Unusual mid-shaft fractures during long-term bisphosphonate therapy.
Topics: Adult; Aged; Alendronate; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis; Risedronic Acid | 2010 |
Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.
Topics: Aged; Alendronate; Cohort Studies; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; Retrospective Studies; Risedronic Acid; Risk Factors | 2009 |
Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Nails; Casts, Surgical; Etidronic Acid; External Fixators; Female; Follow-Up Studies; Fracture Fixation, Internal; Fracture Healing; Fractures, Spontaneous; Humans; Male; Middle Aged; Multivariate Analysis; Osteoporosis; Radiography; Radius Fractures; Risedronic Acid; Time Factors; Wrist Injuries | 2009 |
Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
Topics: Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcium; Diphosphonates; Drugs, Generic; Etidronic Acid; Female; Hip Joint; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Radiography; Retrospective Studies; Risedronic Acid; Therapeutic Equivalency; Vitamin D | 2009 |
[Postmenopausal osteoporosis. Bisphosphonates are not all equal].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drugs, Generic; Etidronic Acid; Female; Germany; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Practice Guidelines as Topic; Retrospective Studies; Risedronic Acid; Time Factors | 2009 |
[Patient compliance program aids therapy success].
Topics: Alendronate; Bone Density Conservation Agents; Calcium; Cholecalciferol; Clinical Trials as Topic; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Risedronic Acid; Time Factors | 2009 |
Synergistic action of statins and nitrogen-containing bisphosphonates in the development of rhabdomyolysis in L6 rat skeletal myoblasts.
Topics: Alendronate; Animals; Apoptosis; Atorvastatin; Bone Density Conservation Agents; Caspases; Cell Line; Diphosphonates; DNA Fragmentation; Drug Synergism; Enzyme Activation; Etidronic Acid; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myoblasts, Skeletal; Pyrroles; Rats; Rhabdomyolysis; Risedronic Acid | 2009 |
Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
Topics: Age Factors; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Epidemiologic Methods; Etidronic Acid; Female; Hip Fractures; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid; United States | 2010 |
Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection.
Topics: Alendronate; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Movement; Diphosphonates; DNA Breaks, Double-Stranded; DNA Damage; Etidronic Acid; Gene Deletion; Humans; Ibandronic Acid; Microscopy, Confocal; Microscopy, Electron; Microtubules; Mutation; Polyisoprenyl Phosphates; Risedronic Acid; RNA Interference; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins | 2009 |
Corticosteroids: no drug prevention of fractures needed.
Topics: Adrenal Cortex Hormones; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Diphosphonates; Etidronic Acid; Fractures, Bone; Humans; Imidazoles; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Steroids; Teriparatide; Vitamin D; Zoledronic Acid | 2009 |
Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; California; Cross-Sectional Studies; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Jaw Diseases; Male; Osteonecrosis; Prevalence; Risedronic Acid; Surveys and Questionnaires; Tooth Extraction | 2010 |
A retrospective clinical and radiographic study on healing of periradicular lesions in patients taking oral bisphosphonates.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Composite Resins; Diphosphonates; Etidronic Acid; Follow-Up Studies; Gutta-Percha; Humans; Ibandronic Acid; Middle Aged; Periapical Diseases; Radiography; Retrospective Studies; Risedronic Acid; Root Canal Filling Materials; Root Canal Preparation; Single-Blind Method; Treatment Outcome; Wound Healing | 2009 |
Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading.
Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Imidazoles; Osteogenesis; Osteoporosis; Ovariectomy; Rats; Risedronic Acid; Zoledronic Acid | 2010 |
Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity.
Topics: Alendronate; Animals; Bone Density; Bone Matrix; Calcification, Physiologic; Diphosphonates; Dogs; Etidronic Acid; Female; Risedronic Acid; Treatment Outcome | 2010 |
Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Etidronic Acid; Female; Humans; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Peptide Fragments; Peptides; Procollagen; Risedronic Acid | 2009 |
Morphological assessment of basic multicellular unit resorption parameters in dogs shows additional mechanisms of bisphosphonate effects on bone.
Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Cell Aggregation; Cell Proliferation; Diphosphonates; Dogs; Dose-Response Relationship, Drug; Etidronic Acid; Female; Humans; Models, Animal; Osteoclasts; Osteoporosis, Postmenopausal; Risedronic Acid; Treatment Outcome | 2010 |
Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Costs and Cost Analysis; Etidronic Acid; Female; Fractures, Bone; Hip Fractures; Humans; Italy; Male; Osteoporosis; Quality of Life; Risedronic Acid | 2010 |
Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Ear, External; Etidronic Acid; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Inflammation Mediators; Injections, Intraperitoneal; Injections, Subcutaneous; Interleukin-1; Male; Mice; Mice, Inbred BALB C; Necrosis; Osteonecrosis; Osteosclerosis; Pamidronate; Pravastatin; Radionuclide Imaging; Radiopharmaceuticals; Risedronic Acid; Technetium; Tibia; Time Factors; Zoledronic Acid | 2010 |
An in vitro assay to measure targeted drug delivery to bone mineral.
Topics: Alendronate; Anabolic Agents; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Drug Delivery Systems; Durapatite; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Nuclear Magnetic Resonance, Biomolecular; Pamidronate; Risedronic Acid; Zoledronic Acid | 2010 |
High level of serum undercarboxylated osteocalcin in patients with incident fractures during bisphosphonate treatment.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Osteocalcin; Osteoporosis; Risedronic Acid; Risk Factors | 2010 |
Intravenous zoledronic acid: what are the indications for male osteoporosis?
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Humans; Imidazoles; Male; Osteoporosis; Parathyroid Hormone; Risedronic Acid; Risk Factors; Testosterone; Zoledronic Acid | 2010 |
How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Dental Care; Diphosphonates; Etidronic Acid; Female; Health Knowledge, Attitudes, Practice; Humans; Ibandronic Acid; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Osteoporosis; Patient Education as Topic; Risedronic Acid; Risk Factors; Time Factors | 2010 |
Atypical femoral fractures and bisphosphonate use.
Topics: Aged; Aged, 80 and over; Alendronate; Diphosphonates; Etidronic Acid; Female; Femoral Fractures; Humans; Male; Osteoporosis; Risedronic Acid; Risk Factors | 2010 |
Histology of an undisplaced femoral fatigue fracture in association with bisphosphonate treatment. Frozen bone with remodelling at the crack.
Topics: Alendronate; Bone Density Conservation Agents; Bone Nails; Bone Resorption; Etidronic Acid; Female; Femoral Fractures; Fracture Fixation, Intramedullary; Fractures, Stress; Humans; Middle Aged; Radiography; Risedronic Acid | 2010 |
In vivo microfocal computed tomography and micro-magnetic resonance imaging evaluation of antiresorptive and antiinflammatory drugs as preventive treatments of osteoarthritis in the rat.
Topics: Alendronate; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Disease Models, Animal; Drug Therapy, Combination; Epiphyses; Etidronic Acid; Female; Femur; Magnetic Resonance Imaging; Meloxicam; Osteoarthritis, Knee; Osteophyte; Rats; Rats, Sprague-Dawley; Risedronic Acid; Stifle; Thiazines; Thiazoles; Tibia; Tomography, X-Ray Computed; Water | 2010 |
Immediate loading in mandible full-arch: pilot study in patients with osteoporosis in bisphosphonate therapy.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Dental Arch; Dental Prosthesis, Implant-Supported; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Immediate Dental Implant Loading; Male; Mandible; Middle Aged; Osteoporosis; Pilot Projects; Radiography, Panoramic; Risedronic Acid; Tooth Extraction; Tooth Socket; Treatment Outcome | 2012 |
[Incidence of hip fractures due to osteoporosis in relation to the prescription of drugs for their prevention and treatment in Galicia, Spain].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Drug Prescriptions; Etidronic Acid; Female; Hip Fractures; Humans; Incidence; Male; Middle Aged; Organometallic Compounds; Osteoporotic Fractures; Retrospective Studies; Risedronic Acid; Spain; Thiophenes | 2011 |
Greater magnitude of turnover suppression occurs earlier after treatment initiation with risedronate than alendronate.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Remodeling; Diaphyses; Etidronic Acid; Female; Fluorescent Dyes; Rabbits; Risedronic Acid; Spine; Tibia; Time Factors | 2011 |
Risk of upper gastrointestinal tract events in risedronate users switched to alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Databases, Factual; Drug Substitution; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Retrospective Studies; Risedronic Acid; Risk Assessment; United Kingdom; Upper Gastrointestinal Tract | 2010 |
[Jaw osteonecrosis induced by oral biphosphonates: 12 cases].
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alendronate; Autoimmune Diseases; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chronic Disease; Delayed Diagnosis; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Female; Follow-Up Studies; Humans; Jaw Diseases; Male; Mandibular Diseases; Middle Aged; Osteonecrosis; Osteoporosis; Risedronic Acid; Time Factors; Tooth Extraction; Treatment Outcome | 2010 |
Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cohort Studies; Cost-Benefit Analysis; Denosumab; Etidronic Acid; Female; Humans; Markov Chains; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Patient Compliance; Quality-Adjusted Life Years; RANK Ligand; Risedronic Acid; Thiophenes | 2011 |
Hip structure analysis of bisphosphonate-treated Japanese postmenopausal women with osteoporosis.
Topics: Aged; Alendronate; Asian People; Diphosphonates; Etidronic Acid; Female; Hip; Humans; Japan; Osteoporosis, Postmenopausal; Radiography; Risedronic Acid | 2011 |
Response of postpoliomyelitis patients to bisphosphonate treatment.
Topics: Administration, Oral; Alendronate; Bone Density; Bone Density Conservation Agents; Case-Control Studies; Etidronic Acid; Female; Fractures, Bone; Humans; Linear Models; Male; Middle Aged; Postpoliomyelitis Syndrome; Retrospective Studies; Risedronic Acid | 2010 |
Outcome of patients with early breast cancer receiving nitrogen-containing bisphosphonates: a comparative analysis from the Metropolitan Detroit Cancer Surveillance System.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Michigan; Middle Aged; Neoplasm Staging; Population Surveillance; Registries; Retrospective Studies; Risedronic Acid; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2010 |
Osteoporosis medication and reduced mortality risk in elderly women and men.
Topics: Aged; Aged, 80 and over; Alendronate; Algorithms; Bone Density Conservation Agents; Cohort Studies; Comorbidity; Etidronic Acid; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mortality; Osteoporosis; Osteoporotic Fractures; Risedronic Acid; Risk Factors | 2011 |
Adherence to osteoporosis medications amongst Singaporean patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Retrospective Studies; Risedronic Acid; Singapore | 2012 |
Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Etidronic Acid; Female; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Male; Medication Adherence; Middle Aged; Organometallic Compounds; Osteoporosis; Raloxifene Hydrochloride; Registries; Retrospective Studies; Risedronic Acid; Sweden; Thiophenes | 2011 |
Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Mandibular Diseases; Maxillary Diseases; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Tooth Extraction; Tooth Socket; Zoledronic Acid | 2012 |
Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Remodeling; Case-Control Studies; Diphosphonates; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Risedronic Acid | 2011 |
Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
Topics: Aged; Alendronate; Analysis of Variance; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Matrix; Crystallization; Drug Administration Schedule; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Risedronic Acid; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Teriparatide; Treatment Outcome | 2011 |
Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Comparative Effectiveness Research; Diphosphonates; Drug Costs; Etidronic Acid; Female; Follow-Up Studies; Fractures, Bone; Humans; Ibandronic Acid; Insurance Claim Review; Longitudinal Studies; Male; Managed Care Programs; Medication Adherence; Middle Aged; Osteoporosis; Regression Analysis; Retrospective Studies; Risedronic Acid; United States | 2011 |
The association between automatic generic substitution and treatment persistence with oral bisphosphonates.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substitution; Drugs, Generic; Etidronic Acid; Female; Humans; Male; Medication Adherence; Osteoporosis; Retrospective Studies; Risedronic Acid; Sweden; Time Factors | 2012 |
Gastric ulcerogenic and healing impairment effects of risedronate, a nitrogen-containing bisphosphonate in rats. Comparison with alendronate and minodronate.
Topics: Alendronate; Animals; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Imidazoles; Male; Nitrogen; Rats; Rats, Sprague-Dawley; Risedronic Acid; Stomach Ulcer; Wound Healing | 2011 |
Paget disease of bone - an update.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Humans; Imidazoles; Middle Aged; Osteitis Deformans; Risedronic Acid; Zoledronic Acid | 2012 |
Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
Topics: Administration, Oral; Aged; Alendronate; Cohort Studies; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Femoral Fractures; Hip Fractures; Humans; Incidence; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Risedronic Acid; United States | 2012 |
Pharmacovigilance of oral bisphosphonates: adverse effects manifesting in the soft tissue of the oral cavity.
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Alendronate; Blister; Bone Density Conservation Agents; Diphosphonates; Drug Monitoring; Etidronic Acid; Female; Gingival Diseases; Humans; Male; Middle Aged; Mouth Diseases; Oral Ulcer; Pharmacovigilance; Risedronic Acid; Sweden; Time Factors; Tongue Diseases | 2012 |
Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Asian People; Bone Density; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Injections, Intravenous; Longitudinal Studies; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Postmenopause; Retrospective Studies; Risedronic Acid | 2012 |
Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; Female; Fractures, Stress; Hip Fractures; Humans; Middle Aged; Osteoporosis; Risedronic Acid | 2011 |
Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; France; Glucocorticoids; Humans; Incidence; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid | 2013 |
[Simultaneous determination of alendronate, pamidronate, ibandronate and risedronate using ion chromatography with integrated pulsed amperometric detection].
Topics: Alendronate; Chromatography, Ion Exchange; Diphosphonates; Electrochemical Techniques; Etidronic Acid; Humans; Ibandronic Acid; Pamidronate; Risedronic Acid | 2012 |
Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cohort Studies; Cost-Benefit Analysis; Denosumab; Etidronic Acid; Female; Humans; Markov Chains; Middle Aged; Models, Econometric; Ontario; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Risedronic Acid | 2012 |
Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Algorithms; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Drug Costs; Etidronic Acid; Female; Health Care Costs; Humans; Middle Aged; Models, Econometric; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Quality of Life; RANK Ligand; Risedronic Acid; Risk Assessment; Thiophenes; United Kingdom | 2013 |
The observational study of delayed wound healing after tooth extraction in patients receiving oral bisphosphonate therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Antibiotic Prophylaxis; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Dental Caries; Diphosphonates; Etidronic Acid; Female; Humans; Male; Middle Aged; Oral Fistula; Periapical Periodontitis; Periodontitis; Risedronic Acid; Risk Factors; Time Factors; Tooth Extraction; Wound Healing | 2013 |
Persistence with osteoporosis medication among newly-treated osteoporotic patients.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Male; Medication Adherence; Middle Aged; Osteoporosis; Patient Compliance; Risedronic Acid | 2013 |
Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Hip Fractures; Humans; Incidence; Medication Adherence; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid; Treatment Outcome; United States | 2013 |
Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans.
Topics: Aged; Alendronate; Barrett Esophagus; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Endoscopy, Digestive System; Etidronic Acid; Female; Gastroesophageal Reflux; Helicobacter Infections; Hernia, Hiatal; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Osteoporosis; Proton Pump Inhibitors; Risedronic Acid; Risk Factors; United States; Veterans; Waist-Hip Ratio | 2013 |
Oral bisphosphonate-related osteonecrosis of the jaws in dental implant patients: a case series.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Dental Implants; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Hypertension; Ibandronic Acid; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Retrospective Studies; Risedronic Acid; Risk Factors; Time Factors | 2013 |
Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Diphosphonates; Drug Costs; Etidronic Acid; Female; Health Care Costs; Humans; Insurance, Health, Reimbursement; Markov Chains; Osteoporosis, Postmenopausal; Risedronic Acid; Sweden; Thiophenes; United States | 2013 |
Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Arthritis, Rheumatoid; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diabetes Complications; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Imidazoles; Infusions, Parenteral; Japan; Male; Middle Aged; Oral Surgical Procedures; Osteoporosis; Prostatic Neoplasms; Risedronic Acid; Treatment Outcome; Wound Healing; Zoledronic Acid | 2013 |
Osteoporosis drugs in real-world clinical practice: an analysis of persistence.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substitution; Etidronic Acid; Female; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Retrospective Studies; Risedronic Acid; Thiophenes | 2013 |
Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Managed Care Programs; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Teriparatide; United States; Zoledronic Acid | 2014 |
Risedronate improves bone architecture and strength faster than alendronate in ovariectomized rats on a low-calcium diet.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Calcium; Etidronic Acid; Female; Food, Formulated; Fractures, Bone; Ovariectomy; Rats; Rats, Sprague-Dawley; Risedronic Acid; Weight-Bearing | 2014 |
A simple evaluation method for early detection of bisphosphonate-related osteonecrosis of the mandible using computed tomography.
Topics: Administration, Intravenous; Administration, Oral; Alendronate; Alveolar Process; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Early Diagnosis; Etidronic Acid; Female; Humans; Image Processing, Computer-Assisted; Imidazoles; Male; Mandible; Mandibular Diseases; Middle Aged; Osteolysis; Osteosclerosis; Pamidronate; Risedronic Acid; Risk Factors; Time Factors; Tomography, X-Ray Computed; Zoledronic Acid | 2014 |
Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Etidronic Acid; Female; Femur Neck; Follow-Up Studies; Hip Joint; Humans; Lumbar Vertebrae; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid; Risk Factors; Smoking; Treatment Failure | 2014 |
Bisphosphonate-associated atypical subtrochanteric femur fractures in the older patient.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Femoral Fractures; Humans; Osteoporosis, Postmenopausal; Radiography; Risedronic Acid | 2014 |
Use of strontium ranelate and risk of acute coronary syndrome: cohort study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denmark; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Proportional Hazards Models; Risedronic Acid; Thiophenes | 2014 |
Residual effect after oral bisphosphonate treatment and healthy adherer effects--the Swedish Adherence Register Analysis (SARA).
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Comorbidity; Effect Modifier, Epidemiologic; Etidronic Acid; Female; Hospitalization; Humans; Incidence; Male; Medication Adherence; Middle Aged; Osteoporosis; Osteoporotic Fractures; Registries; Risedronic Acid; Risk Assessment; Sweden; Withholding Treatment | 2015 |
The osteogenic activity of human mandibular fracture haematoma-derived progenitor cells is affected by bisphosphonate in vitro.
Topics: Adult; Aged; Alendronate; Alkaline Phosphatase; Cell Differentiation; Cell Proliferation; Diphosphonates; Etidronic Acid; Female; Fracture Healing; Hematoma; Humans; In Vitro Techniques; Male; Mandibular Fractures; Middle Aged; Osteogenesis; Risedronic Acid | 2015 |
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Hip Fractures; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Spinal Fractures; Teriparatide; Thiophenes; Treatment Outcome; Vitamin D; Zoledronic Acid | 2015 |
Elevation of serum alkaline phosphatase (ALP) level in postmenopausal women is caused by high bone turnover.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Female; Humans; Isoenzymes; Japan; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Retrospective Studies; Risedronic Acid; Treatment Outcome | 2015 |
Comparison between different bone treatments on areal bone mineral density (aBMD) and bone microarchitectural texture as assessed by the trabecular bone score (TBS).
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Denosumab; Dietary Supplements; Female; Humans; Longitudinal Studies; Male; Middle Aged; Osteoporosis; Risedronic Acid; Teriparatide; Testosterone; Vitamin D | 2015 |
Risk of atypical femoral fracture during and after bisphosphonate use.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Cohort Studies; Diphosphonates; Etidronic Acid; Female; Femoral Fractures; Humans; Male; Middle Aged; Osteoporotic Fractures; Radiography; Retrospective Studies; Risedronic Acid; Risk Factors; Sex Factors; Sweden; Time Factors | 2015 |
Perioperative alendronate, risedronate, calcitonin and indomethacin treatment alters femoral stem fixation and periprosthetic bone mineral density in ovariectomized rats.
Topics: Absorptiometry, Photon; Alendronate; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement, Hip; Bone Density; Bone Density Conservation Agents; Calcitonin; Disease Models, Animal; Drug Therapy, Combination; Female; Follow-Up Studies; Indomethacin; Osteoporosis; Ovariectomy; Postoperative Care; Postoperative Complications; Preoperative Care; Rats; Rats, Wistar; Risedronic Acid | 2015 |
Gastrointestinal Events Among Patients Initiating Osteoporosis Therapy: A Retrospective Administrative Claims Database Analysis.
Topics: Administrative Claims, Healthcare; Aged; Alendronate; Databases, Factual; Diphosphonates; Female; Gastrointestinal Diseases; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; Retrospective Studies; Risedronic Acid; United States | 2015 |
Results of a national multicentric study on compliance to treatment with various disphosphonate formulations in patients with postmenopausal osteoporosis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Retrospective Studies; Risedronic Acid | 2015 |
Atypical Femoral Fracture in Rheumatoid Arthritis Patients Treated With Bisphosphonates: A Nested Case-Control Study.
Topics: Absorptiometry, Photon; Aged; Alendronate; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Female; Femoral Fractures; Femur; Genu Valgum; Humans; Ibandronic Acid; Logistic Models; Lumbar Vertebrae; Middle Aged; Multivariate Analysis; Osteoporotic Fractures; Retrospective Studies; Risedronic Acid; Risk Factors; Time Factors | 2016 |
Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Arthritis, Rheumatoid; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Drug Administration Schedule; Drug Substitution; Female; Humans; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Patient Preference; Prospective Studies; Risedronic Acid | 2016 |
Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
Topics: Aged; Alendronate; Body Weight; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Retrospective Studies; Risedronic Acid; Risk Assessment; Withholding Treatment | 2016 |
Urban-rural differences in the uptake of new oral bisphosphonate formulations.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Cholecalciferol; Diphosphonates; Female; Humans; Male; Ontario; Osteoporosis; Patient Acceptance of Health Care; Risedronic Acid; Rural Health; Urban Health | 2016 |
Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX(®) in Portugal.
Topics: Aged; Alendronate; Algorithms; Bone Density Conservation Agents; Cohort Studies; Cost-Benefit Analysis; Denosumab; Female; Hip Fractures; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid | 2016 |
Location of fractures and the characteristics of patients with atypical femoral fractures: analyses of 38 Japanese cases.
Topics: Aged; Aged, 80 and over; Alendronate; Asian People; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Femoral Fractures; Femur; Glucocorticoids; Humans; Imidazoles; Japan; Male; Middle Aged; Proton Pump Inhibitors; Retrospective Studies; Risedronic Acid | 2017 |
Oral Bisphosphonates and Risk of Wet Age-Related Macular Degeneration.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Case-Control Studies; Diphosphonates; Female; Humans; Ibandronic Acid; Male; Odds Ratio; Risedronic Acid; Risk Factors; Wet Macular Degeneration | 2016 |
[Bisphosphonate use and related pharmaceutical issues II].
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Confounding Factors, Epidemiologic; Diphosphonates; Drug Costs; Drug Prescriptions; Drugs, Generic; Humans; Hungary; Ibandronic Acid; Imidazoles; National Health Programs; Osteoporosis; Pamidronate; Retrospective Studies; Risedronic Acid; Zoledronic Acid | 2016 |
Role of Side Effects, Physician Involvement, and Patient Perception in Non-Adherence with Oral Bisphosphonates.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cross-Sectional Studies; Databases, Factual; Female; Humans; Medication Adherence; Middle Aged; Osteoporosis; Risedronic Acid | 2016 |
Alendronate- and risedronate-induced acute polyarthritis.
Topics: Alendronate; Arthritis; Bone Density Conservation Agents; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid | 2016 |
Use of drugs against osteoporosis in the Baltic countries during 2010-2014.
Topics: Alendronate; Baltic States; Bone Density Conservation Agents; Calcium Channel Blockers; Denosumab; Diphosphonates; Drug Utilization; Ergocalciferols; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis; Risedronic Acid | 2016 |
Effect of Sequential Treatment with Bisphosphonates After Teriparatide in Ovariectomized Rats: A Direct Comparison Between Risedronate and Alendronate.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Ovariectomy; Rats; Rats, Sprague-Dawley; Risedronic Acid; Teriparatide | 2017 |
BONE TURNOVER IN OSTEOPOROTIC WOMEN DURING LONG-TERM ORAL BISPHOSPHONATES TREATMENT: IMPLICATIONS FOR TREATMENT FAILURE AND "DRUG HOLIDAY" IN THE REAL WORLD.
Topics: Administration, Intravenous; Administration, Oral; Aged; Alendronate; Amino Acids; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Deprescriptions; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Retrospective Studies; Risedronic Acid; Time Factors; Treatment Failure; Zoledronic Acid | 2017 |
Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Imidazoles; Incidence; Middle Aged; Netherlands; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Registries; Risedronic Acid; Risk Factors; Sweden; Treatment Outcome; Zoledronic Acid | 2017 |
Weekly oral bisphosphonates over 2 years prevent bone loss in cardiac transplant patients.
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Female; Follow-Up Studies; Heart Transplantation; Humans; Male; Middle Aged; Osteoporosis; Prognosis; Risedronic Acid; Risk Factors; Time Factors | 2017 |
Management of Corticosteroid-Induced Osteoporosis: A Practical Approach for the Dermatologist.
Topics: Adrenal Cortex Hormones; Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Dermatology; Diagnostic Tests, Routine; Disease Management; Female; Humans; Life Style; Male; Middle Aged; Osteoporosis; Risedronic Acid; Vitamin D | 2018 |
Bisphosphonates prevent age-related weight loss in Japanese postmenopausal women.
Topics: Aged; Alendronate; Asian People; Biomarkers; Body Composition; Body Mass Index; Body Weight; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Humans; Linear Models; Middle Aged; Postmenopause; Risedronic Acid; Risk Factors; Weight Loss | 2018 |
Long-term control of Paget's disease of bone with low-dose, once-weekly, oral bisphosphonate preparations, in a "real world" setting.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Humans; Male; Middle Aged; Osteitis Deformans; Remission Induction; Retrospective Studies; Risedronic Acid | 2019 |
Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Canada; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Prospective Studies; Risedronic Acid; Risk Factors; Risk Reduction Behavior | 2019 |
Symptoms and Upper Gastrointestinal Mucosal Injury Associated with Bisphosphonate Therapy.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Gastrointestinal Tract; Humans; Japan; Male; Middle Aged; Mucous Membrane; Osteoporosis; Risedronic Acid | 2019 |
Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Costs; Female; France; Health Care Costs; Humans; Markov Chains; Middle Aged; Models, Econometric; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Quality-Adjusted Life Years; Risedronic Acid | 2019 |
Incidence of osteonecrosis of the jaw by the use of osteoclast inhibitors in patients with bone metastases: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Female; Humans; Incidence; Male; Mexico; Middle Aged; Osteoclasts; Retrospective Studies; Risedronic Acid; Time Factors; Zoledronic Acid | 2019 |
Time trends in oral bisphosphonate initiation in Ontario, Canada over 20 years reflect drug policy and healthcare delivery changes.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Male; Ontario; Osteoporosis; Pharmacoepidemiology; Risedronic Acid; Sex Factors; Time Factors | 2019 |
Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition.
Topics: Alendronate; Bone Density Conservation Agents; Consensus; Diphosphonates; Humans; Osteoporosis; Osteoporotic Fractures; Risedronic Acid | 2020 |
Effect of continuous long-term treatment for 10 years with bisphosphonate on Japanese osteoporosis patients.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Asian People; Bone Density; Calcium; Collagen Type I; Diphosphonates; Female; Humans; Japan; Osteoporosis; Osteoporosis, Postmenopausal; Peptides; Phosphorus; Retrospective Studies; Risedronic Acid; Tartrate-Resistant Acid Phosphatase; Time Factors; Treatment Outcome | 2020 |
Temporal Trends and Factors Associated with Bisphosphonate Discontinuation and Restart.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Humans; Medicare; Risedronic Acid; United States | 2020 |
Novel combinatorial transdermal drug delivery of alendronate with risedronate for the treatment of osteoporosis.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Calcium; Drug Delivery Systems; Drug Therapy, Combination; Female; Osteoporosis; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Risedronic Acid; Transdermal Patch | 2019 |
Bisphosphonates in the management of Paget's disease.
Topics: Alendronate; Diphosphonates; Humans; Osteitis Deformans; Risedronic Acid; Zoledronic Acid | 2020 |
Upper gastrointestinal safety of oral bisphosphonate in hospitalized patients.
Topics: Administration, Oral; Adult; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Humans; Inpatients; Middle Aged; Osteoporosis; Prospective Studies; Risedronic Acid | 2021 |
The relation of oral bisphosphonates to bone marrow lesion volume among women with osteoarthritis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Marrow; Diphosphonates; Female; Humans; Ibandronic Acid; Longitudinal Studies; Magnetic Resonance Imaging; Middle Aged; Osteoarthritis, Knee; Propensity Score; Risedronic Acid | 2020 |
Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis.
Topics: Alendronate; Bone Density Conservation Agents; Data Analysis; Diphosphonates; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid | 2022 |
Comparative Fracture Risk During Osteoporosis Drug Holidays After Long-Term Risedronate Versus Alendronate Therapy : A Propensity Score-Matched Cohort Study.
Topics: Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Canada; Cohort Studies; Female; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Propensity Score; Risedronic Acid | 2022 |
Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada.
Topics: Alendronate; Antibodies, Monoclonal; Bone Density Conservation Agents; Cost-Benefit Analysis; Female; Humans; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Postmenopause; Quality-Adjusted Life Years; Risedronic Acid | 2022 |
Medication-Related Osteonecrosis of the Jaw: 14 Years' Retrospective Study on Pathogenetic Trigger Events.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Humans; Precipitating Factors; Retrospective Studies; Risedronic Acid; Zoledronic Acid | 2022 |
Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Denosumab; Diphosphonates; Female; Humans; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Retrospective Studies; Risedronic Acid; Spinal Fractures; Zoledronic Acid | 2023 |
Utilization patterns and factors associated with persistence of new users of anti-osteoporosis treatment in Denmark: a population-based cohort study.
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Denmark; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Risedronic Acid | 2023 |
Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid | 2023 |
Zoledronate and osteonecrosis of the jaw in osteoporosis: incidence and risk factors. Analysis of the French Pharmacovigilance Database.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Denosumab; Diphosphonates; Humans; Incidence; Osteoporosis; Pharmacovigilance; Risedronic Acid; Risk Factors; Zoledronic Acid | 2023 |
Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system.
Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Femur; Humans; Ibandronic Acid; Osteoporosis; Pamidronate; Pharmaceutical Preparations; Risedronic Acid | 2023 |
Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain.
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Cost-Benefit Analysis; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Risedronic Acid; Spain | 2023 |